<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="chapter-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><?noissn?><front><journal-meta><journal-id journal-id-type="publisher-id">978-3-319-02096-9</journal-id><journal-id journal-id-type="doi">10.1007/978-3-319-02096-9</journal-id><journal-id journal-id-type="nlm-ta">Liver Immunology</journal-id><journal-title-group><journal-title>Liver Immunology</journal-title><journal-subtitle>Principles and Practice</journal-subtitle></journal-title-group><isbn publication-format="print">978-3-319-02095-2</isbn><isbn publication-format="electronic">978-3-319-02096-9</isbn></journal-meta><article-meta><article-id pub-id-type="pmcid">7120377</article-id><article-id pub-id-type="publisher-id">12</article-id><article-id pub-id-type="doi">10.1007/978-3-319-02096-9_12</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Viral Diseases of the Liver</article-title></title-group><contrib-group content-type="book editors"><contrib contrib-type="editor"><name><surname>Gershwin</surname><given-names>M. Eric</given-names></name><address><email>megershwin@ucdavis.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="editor"><name><surname>Vierling</surname><given-names>John M.</given-names></name><address><phone>713798-4842</phone><fax>713798-8522</fax><email>vierling@bcm.tmc.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="editor"><name><surname>Manns</surname><given-names>Michael P.</given-names></name><address><phone>+49 511 532-3306</phone><email>manns.michael@mh-hannover.de</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution-id institution-id-type="ISNI">0000000419369684</institution-id><institution>Division of Rheumatology, Allergy and Clinical Immunology, </institution><institution>University of California School of Medicine, </institution></institution-wrap>Davis, California USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">000000012160926X</institution-id><institution>Medicine and Surgery, </institution><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, Texas USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.10423.34</institution-id><institution-id institution-id-type="ISNI">0000000095299877</institution-id><institution>Department of Gastroenterology, Hepatology and Endocrinology, </institution><institution>Medical School of Hannover, </institution></institution-wrap>Germany </aff></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Lalazar</surname><given-names>Gadi</given-names></name><address><email>gadi.lalazar@einstein.yu.edu</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ilan</surname><given-names>Yaron</given-names></name><address><email>ilan@hadassah.org.il</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.240283.f</institution-id><institution>Marion Bessin Liver Research Center, Department of Medicine, </institution><institution>Albert Einstein College of Medicine of Yeshiva University, </institution></institution-wrap>Bronx, NY USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.17788.31</institution-id><institution-id institution-id-type="ISNI">0000000122212926</institution-id><institution>Gastroenterology and Liver Units, Department of Medicine, </institution><institution>Hadassah Hebrew University Medical Center, </institution></institution-wrap>Jerusalem, Israel </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>10</month><year>2013</year></pub-date><fpage>159</fpage><lpage>171</lpage><permissions><copyright-statement>&#x000a9; Springer Science+Business Media New York 2014</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p>Viruses other than the classic hepatotropic viruses, hepatitis A through E, may cause hepatic injury [1]. Among these are Epstein&#x02013;Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), varicella zoster virus (VZV), human herpes viruses (HHV) 6, 7, and 8, human parvovirus B19, and adenoviruses (Table 11.1). The clinical presentation of infections with these viruses may be indistinguishable from that associated with infection with classic hepatotropic viruses. The presentation ranges from mild and transient elevation of aminotransferases to acute hepatitis and can also lead to acute liver failure [1]. These viruses should be considered as possible etiologic agents in patients who have acute liver injury and whose serologic markers for the classic hepatotropic viruses are not indicative of an active infection [1]. In the present chapter, we review the clinical manifestations and the potential for immune-mediated liver injury associated with several of these viruses (see summary Table 11.2).</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Liver Transplant Recipient</kwd><kwd>Infectious Mononucleosis</kwd><kwd>Antiviral Prophylaxis</kwd><kwd>Preemptive Therapy</kwd><kwd>Herpes Simplex Virus Hepatitis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, New York 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d29e304"><title>Key Points (6&#x02013;12)</title><p>
<list list-type="order"><list-item><p>A variety of viruses in addition to the classic hepatitis viruses A to E can affect the liver. These include Epstein&#x02013;Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), varicella zoster virus (VZV), human herpes viruses 6, 7, and 8, human parvovirus B19, adenoviruses, and others.</p></list-item><list-item><p>The clinical presentation of infections with these viruses may be indistinguishable from that associated with the &#x0201c;classic&#x0201d; hepatotropic viruses and can range from transient elevation of aminotransferases to liver failure.</p></list-item><list-item><p>Both the innate and adaptive arms of the immune system play a role in the pathogenesis of virally mediated target organ involvement.</p></list-item><list-item><p>In most immune-competent patients an asymptomatic or mild disease occurs, while immune-suppressed patients and organ transplant recipients are at high risk for the development of severe systemic infection.</p></list-item><list-item><p>Antiviral agents have a role in the treatment of immune-compromised patients and in immune-competent patients who present with severe life-threatening disease.</p></list-item><list-item><p>EBV may be associated with increased risk of malignancy and post-transplant lymphoproliferative disorders (PTLDs).</p></list-item></list>
</p></sec><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Viruses other than the classic hepatotropic viruses, hepatitis A through E, may cause hepatic injury [<xref ref-type="bibr" rid="CR1">1</xref>]. Among these are Epstein&#x02013;Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), varicella zoster virus (VZV), human herpes viruses (HHV) 6, 7, and 8, human parvovirus B19, and adenoviruses (Table <xref rid="Tab1" ref-type="table">12.1</xref>). The clinical presentation of infections with these viruses may be indistinguishable from that associated with infection with classic hepatotropic viruses. The presentation ranges from a mild and transient elevation of aminotransferases to acute hepatitis and liver liver failure [<xref ref-type="bibr" rid="CR1">1</xref>]. These viruses should be considered as possible etiologic agents in patients who have acute liver injury and whose serologic markers for the classic hepatotropic viruses are not indicative of an active infection [<xref ref-type="bibr" rid="CR1">1</xref>]. In the present chapter, we review the clinical manifestations and the potential for immune-mediated liver injury associated with several of these viruses (see summary Table <xref rid="Tab2" ref-type="table">12.2</xref>).<table-wrap id="Tab1"><label>Table 12.1</label><caption><p>Non-hepatotropic viruses that may affect the liver</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Herpes viruses: Cytomegalovirus, Epstein&#x02013;Barr virus, varicella zoster virus, human herpes virus 6, human herpes virus 7, and human herpes virus 8</td></tr><tr><td>Adenoviruses</td></tr><tr><td>Arenaviruses: Guanarito virus, Jun&#x000ed;n virus, Lassa fever virus, Machupo virus, and Sabi&#x000e1; virus</td></tr><tr><td>Bunyaviruses: Crimean-Congo hemorrhagic fever virus, Dobrava virus, Hantaan virus, Puumala virus, Rift Valley fever virus, and Seoul virus</td></tr><tr><td>Coronavirus: Severe Acute Respiratory Syndrome Virus</td></tr><tr><td>Erythrovirus: Parvovirus B19</td></tr><tr><td>Filoviruses: Ebola virus and Marburg virus</td></tr><tr><td>Flaviviruses: Dengue, Lujo virus, Kyasanur Forest disease virus, Omsk hemorrhagic fever virus, and yellow fever virus</td></tr><tr><td>Orthomyxoviruses: Influenza</td></tr><tr><td>Picornaviruses: Echovirus</td></tr><tr><td>Reovirus: Colorado tick fever virus, Reovirus 3</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab2"><label>Table 12.2</label><caption><p>Clinical features, diagnosis, and treatment summary table</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Virus</th><th>Population at risk</th><th>Clinical and laboratory features</th><th>Acute liver failure</th><th>Unique complications</th><th>Diagnostic tests</th><th>Treatment</th><th>Effective antiviral medication</th></tr></thead><tbody><tr><td>EBV</td><td><p>IC</p><p>Age &#x0003e;30 (esp. &#x0003e;60)</p><p>XLP</p><p>Solid organ transplant recipients (especially pediatric)</p></td><td><p>Lymphocytosis</p><p>Monocytosis</p><p>Splenomegaly</p><p>Gradually rising liver enzymes</p></td><td><p>Rare</p><p>More common in immunosuppressed patients (60 % in patients with XLP)</p></td><td><p>Splenic rupture</p><p>PTLD</p><p>HLH</p><p>AIH exac.</p></td><td><p>Monospot</p><p>EBV VCA IgM</p><p>PCR (blood and tissue)</p><p>Liver biopsy&#x02014;rarely needed (portal and sinusoidal mononuclear cell infiltration with focal hepatic necrosis or fatty infiltration)</p></td><td><p>ICP: only if severe complications</p><p>Steroids</p><p>Antivirals (if steroid refractory)</p><p>IC: anti-EBV CTLs antivirals</p></td><td><p>Ganciclovir</p><p>Valganciclovir</p><p>Valacyclovir</p><p>Famiclovir</p><p>Foscarent</p></td></tr><tr><td>CMV</td><td><p>IC</p><p>Solid organ transplant recipients</p><p>Neonates (congenital CMV)</p><p>IBD</p></td><td><p>Hepatosplenomegaly</p><p>Aminotransferases lower than in &#x0201c;classic viral hepatitis&#x0201d;</p><p>Leukopenia</p><p>Thrombocytopenia</p></td><td><p>Rare</p><p>More common in IC</p></td><td>Graft rejection and loss encephalitis, pneumonitis, hepatitis, uveitis, retinitis, colitis</td><td><p>CMV IgM</p><p>PCR (blood and tissue)</p><p>Liver biopsy&#x02014;important (giant multinucleated cell reaction with an inflammatory response, multifocal necrosis, biliary stasis. Large nuclear inclusions in hepatocytes or bile duct epithelium)</p><p>Immuno-histochemistry</p></td><td><p>ICP&#x02014;only in severe end organ disease</p><p>IC&#x02014;antivirals&#x02009;&#x000b1;&#x02009;IVIG</p><p>Organ transplant recipients&#x02014;prophylactic vs. preemptive treatment</p></td><td><p>Ganciclovir</p><p>Valganciclovir</p><p>Foscarnet</p><p>Cidofovir</p><p>CMV hyperimmune globulin</p><p>Leflunomide</p></td></tr><tr><td>HSV</td><td><p>IC</p><p>Pregnancy (third trimester)</p><p>Neonates</p></td><td><p>Leukopenia, thrombocytopenia, relatively mild elevation in bilirubin</p><p>Mucocutaneous lesions (50 %)</p></td><td><p>Rare</p><p>More common in pregnancy, IC, and neonates</p></td><td><p>Esophagitis</p><p>Pneumonitis</p></td><td><p>HSV PCR (blood and tissue)</p><p>Liver biopsy&#x02014;essential (focal&#x02014;extensive, hemorrhagic, or coagulative hepatocyte necrosis, limited inflammatory response). Typical intranuclear inclusions (Cowdry type A) at the margins of the foci of necrosis</p></td><td>Early high-dose acyclovir</td><td>Acyclovir</td></tr><tr><td>VZV</td><td><p>Adults</p><p>IC</p><p>Liver transplant recipients</p></td><td>Cutaneous rash</td><td><p>Rare</p><p>More common in immunocompromised individuals</p></td><td>Graft loss</td><td><p>Viral isolation from skin lesions</p><p>HSV PCR (blood and tissue)</p><p>Liver biopsy (foci of coagulative necrosis and intranuclear inclusions with an inflammatory response)</p></td><td>Early therapy with acyclovir in severe disease or IC patients</td><td>Acyclovir</td></tr></tbody></table><table-wrap-foot><p>
<italic>IC</italic> immunocompromised, <italic>ICP</italic> immunocompetent, <italic>XLP</italic> X-linked lymphoproliferative disorder, <italic>PTLD</italic> post-transplant lymphoproliferative disorder, <italic>HLH</italic> hemophagocytic lymphohistiocytosis, <italic>AIH</italic> autoimmune hepatitis, <italic>CTLs</italic> cytotoxic T lymphocytes</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec2"><title>Epstein&#x02013;Barr Virus</title><sec id="Sec3"><title>EBV Infection</title><p>EBV is a double-stranded DNA virus that is a member of the gamma herpes virus family [<xref ref-type="bibr" rid="CR1">1</xref>]. Its genome consists of a linear DNA molecule that encodes nearly 100 viral proteins. Expression of different combinations of these proteins allows the virus to establish different forms of infection [<xref ref-type="bibr" rid="CR2">2</xref>]. Cell entry and translocation of EBV particles to the nucleus is confirmed by detection of the EBV genome in isolated nuclei [<xref ref-type="bibr" rid="CR3">3</xref>]. While B cells in the oropharynx may be the primary site of infection, resting memory B cells are thought to be the site of persistence of EBV throughout the body. EBV has evolved several strategies to evade immune system recognition and to establish latent infection in memory B cells, where it resides lifelong without any consequence in the majority of individuals [<xref ref-type="bibr" rid="CR4">4</xref>]. After infecting B lymphocytes, the linear EBV genome becomes circular, forming an episome, which usually remains latent in these B cells. Only ten of the viral proteins are expressed in latently infected B cells in vitro. Limited gene expression during latency ensures successful escape from cytotoxic T lymphocyte (CTL) recognition [<xref ref-type="bibr" rid="CR2">2</xref>]. EBV shares the tendency of establishing latency in the host with other herpes viruses [<xref ref-type="bibr" rid="CR2">2</xref>]. Viral replication is spontaneously activated in only a small percentage of latently infected B cells [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>EBV infection is a common and lifelong infection affecting over 90 % of humans worldwide. The virus replicates in nasopharyngeal epithelial cells, and seropositive persons actively shed the virus in saliva [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Transmission of EBV usually occurs by contact with oral secretions.</p><p>Diagnosis of EBV infection is based on clinical features and on laboratory and serological findings indicative of a recent infection. The most common is leukocytosis, which appears in 70 % of cases, predominantly as lymphocytosis and monocytosis, as well as mild thrombocytopenia in up to 50 % of affected individuals. EBV-specific IgG and IgM antibodies directed against the viral capsid antigens (VCA), the early antigens (EBV anti-D and anti-R), the nuclear antigen (EBVNA), and soluble complement-fixing antigens (anti-S) are used for viral detection [<xref ref-type="bibr" rid="CR1">1</xref>]. The &#x0201c;monospot&#x0201d; test that detects heterophil antibodies is sensitive but not specific. In the vast majority of cases, there is no indication for liver biopsy, but when performed there may be portal and sinusoidal mononuclear cell infiltration with focal hepatic necrosis or fatty infiltration [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Specifically, the diagnosis of EBV hepatitis is established based on the combination of elevated aminotransferases, serology compatible with active EBV infection, typical findings on liver biopsy, and demonstration of the presence of the viral genome in liver tissue by various molecular methods.</p></sec><sec id="Sec4"><title>The Role of the Immune System in EBV Infection</title><p>Imbalances in the equilibrium between the virus and the host&#x02019;s immune system lead to the development of liver damage in EBV-infected patients. EBV can also be involved in the development of tumors such as lymphoproliferative disorders, Hodgkin&#x02019;s lymphoma, Burkitt&#x02019;s lymphoma, and nasopharyngeal carcinoma [<xref ref-type="bibr" rid="CR4">4</xref>]. The demonstration that immunotherapeutic approaches are effective for some of these cancer patients further supports a role for the immune system in disease pathogenesis [<xref ref-type="bibr" rid="CR4">4</xref>]. In the context of EBV-related tumors, the expression of viral antigens by malignant cells makes them suitable targets for immune therapy. Infusion of EBV-specific CTLs has proved to be safe and effective and induces protective antiviral immunity, which is lacking in EBV-associated malignancy [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>Both the innate and the adaptive arms of the immune system play a role in anti-EBV immunity [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. EBV interacts with NK cells, neutrophils, monocytes, and macrophages, as well as with epithelial cells that are relevant to viral resistance [<xref ref-type="bibr" rid="CR4">4</xref>]. The tonsils are the primary site for EBV infection. EBV triggers monocyte TLRs, inducing maturation of DCs, which activate CD16&#x02013;CD56 bright NK cells via IL12. NK cells hamper pathogen entry at mucosal sites, thus restricting EBV infection until the adaptive immunity establishes viral immune control [<xref ref-type="bibr" rid="CR9">9</xref>]. IFN-<italic>&#x003b3;</italic> secreted by DC-activated NK cells is associated with delayed latent EBV antigen expression. It inhibits B-cell transformation, decreasing their proliferation during the first week following infection [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. IFN-<italic>&#x003b3;</italic> also promotes an EBV-specific adaptive immune response by favoring a Th1-polarization.</p><p>Early after primary viral infection, NK cells are thought to limit the viral burden until virus-specific T cells are able to eliminate the infection or maintain viral titers at low levels. Innate immunity uses several &#x0201c;pattern recognition&#x0201d; receptors to sense pathogen-associated molecular patterns (PAMPs) [<xref ref-type="bibr" rid="CR4">4</xref>]. Toll-like receptor (TLR) activation has downstream effects during primary EBV infection that favor viral latency or reactivation and facilitate immune control. Intact viral particles are recognized by the membrane surface receptor TLR2 [<xref ref-type="bibr" rid="CR11">11</xref>]. Following viral entry into cells, viral DNA is recognized by TLR9. Dual interactions through TLR2 on the cell membrane and intracellular TLR9 lead to a rapid production of IL-8, initiating an effective antiviral immunity.</p><p>Innate lymphocytes also play a role in resistance to EBV-associated malignancies. Mutations in SAP (signaling-lymphocyte activation-molecule-(SLAM)-associated protein) are associated with loss of EBV-specific immune control [<xref ref-type="bibr" rid="CR4">4</xref>]. During EBV latency, the virus develops mechanisms of immune escape from innate immunity-dependent mechanisms, including the inhibition of NK cell activation through EBV-induced gene 3 (EBI3) [<xref ref-type="bibr" rid="CR4">4</xref>]. EBV-transformed B lymphocytes express high levels of EBI3 protein, which has immunosuppressive activity [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>The EBV genome is also detected in non-B cells, including phagocytes. Monocytes and macrophages are involved in the uptake of small vesicles called exosomes that contain viral mRNA. Exosomes play a role during the early phases of EBV infection and also involve innate immunity-related cell types that are not targeted by the virus [<xref ref-type="bibr" rid="CR4">4</xref>]. An increase in neutrophils is observed during the initial phases of EBV infection, whereas a transient episode of acute neutropenia is often observed in infectious mononucleosis (IM) during the third week of illness [<xref ref-type="bibr" rid="CR13">13</xref>]. Infected neutrophils rapidly die by apoptosis [<xref ref-type="bibr" rid="CR14">14</xref>]. Secretion of various cytokines and chemokines (e.g., IL-1, IL-8, MIP-1<italic>&#x003b1;</italic>, LTB4, and reactive superoxide anion) promotes the development of EBV-specific immunity, while upregulation of IL-1R and induction of apoptosis in neutrophils inhibit anti-EBV immune responses [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Episodes of monocytopenia are observed during the acute phase of IM [<xref ref-type="bibr" rid="CR4">4</xref>]. Patients with EBV-associated malignancy show a deficiency in monocyte-mediated ADCC, suggesting that monocyte functions are affected during the course of EBV infection. This is also demonstrated by the reduced phagocytic activity observed in EBV-infected monocytes [<xref ref-type="bibr" rid="CR3">3</xref>]. EBV infection inhibits the functional ability of macrophages to respond to bacterial challenge by reducing their phagocytic potential [<xref ref-type="bibr" rid="CR15">15</xref>]. By inhibiting the differentiation of monocytes into mature DCs, EBV temporarily halts the onset of immune responses during primary infection, enabling efficient viral replication. This permits the accumulation of a large pool of virus-infected B lymphocytes, allowing access of the virus to the memory B-cell compartment, interfering with the functions of DCs during the initiation of virus-specific immunity, and modifying the profile of secreted cytokines, thus creating a favorable environment for viral propagation [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p>CTLs are major determinants in the control of acute EBV infection and are directed against both lytic and latent antigens [<xref ref-type="bibr" rid="CR16">16</xref>]. About half of the total CD8+ T cells in acute infection are specific for a single lytic EBV epitope, and most of these epitope-specific cells have an activated/memory phenotype. In the late stages of infection, the frequency of epitope-specific CD8+ T cells directed against latent EBV proteins selectively increases, confirming that CTLs are the most important cells for limiting infection in the convalescent phase of virus infection.</p><p>In lytic infections, the virus expresses a full complement of immediate-early, early, and late lytic cycle proteins and is capable of replicating within the host cell [<xref ref-type="bibr" rid="CR16">16</xref>]. In latent infection, the virus expresses fewer proteins, does not replicate, and is able to persist within the host cell. EBV has developed the ability to rapidly promote the expression of its own genes while simultaneously shutting down the transcriptional program of its host cell [<xref ref-type="bibr" rid="CR4">4</xref>]. TNF-<italic>&#x003b1;</italic> levels are increased in IM patients, indicating its importance in ongoing antiviral response. However, the entire virus inhibits TNF-<italic>&#x003b1;</italic> secretion by monocytes and macrophages [<xref ref-type="bibr" rid="CR3">3</xref>]. EBV downregulates TNF-<italic>&#x003b1;</italic> mRNA transcripts via suppressive action at the transcriptional level [<xref ref-type="bibr" rid="CR4">4</xref>]. EBV proteins can also modulate IFN signaling. This effect promotes viral persistence and may also contribute to tumor development [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>EBV reactivation associated with increased specific CTL-response to a lytic EBV epitope can lead to EBV-associated chronic hepatitis [<xref ref-type="bibr" rid="CR18">18</xref>]. EBV reactivation in these patients is based on an increased percentage of terminally differentiated CD28-CD27-CD8+ T cells, suggestive of chronic antigen stimulation [<xref ref-type="bibr" rid="CR18">18</xref>]. Diminished expression of the co-stimulatory molecules CD28 and CD27 compromises CD8+ reactivation, making cells more resistant to apoptosis [<xref ref-type="bibr" rid="CR19">19</xref>]. A T-cell pool with low expression of CD28 and CD27 has low ability to control reactivation of virus and is a typical finding in an elderly group. Similar changes were found in younger patients under chronic CMV and EBV antigen stimulation [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p>While cellular immunity is fundamental for controlling both the primary and persistent phases of EBV propagation, the humoral response controls viral spread in late phases of infection [<xref ref-type="bibr" rid="CR21">21</xref>]. EBV stimulates strong humoral responses to lytic cycle proteins. IgM and developing IgG responses to nucleocapsid and envelope proteins are detectable in primary EBV infection [<xref ref-type="bibr" rid="CR4">4</xref>]. IgG responses to immediate-early and early lytic cycle proteins and to the latent proteins EBNA1 and 2 are also detectable, together with neutralizing antibodies directed against gp350 [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec5"><title>Clinical Manifestations of Acute Liver Involvement in EBV Infection</title><p>Various clinical conditions have been associated with EBV, including infectious mononucleosis, Burkitt&#x02019;s lymphoma, nasopharyngeal carcinoma, Hodgkin&#x02019;s disease, peripheral T-cell lymphoma, and post-transplant lymphoproliferative disorder (PTLD) [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p><p>Primary EBV infection takes place in the oropharyngeal region, to which the virus is conveyed by saliva droplets from infected individuals. Primary infection leads to transient viremia followed by a strong T-cell adaptive immune response that holds the infection latent in immunocompetent individuals [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. If infection is delayed to adolescence or adulthood, it can cause infectious mononucleosis (IM), a self-resolving lymphoid disorder largely resulting from an uncontrolled T-cell reaction directed against EBV-infected cells. In IM patients, EBV is exclusively found in B blasts that proliferate under the influence of latent genes [<xref ref-type="bibr" rid="CR4">4</xref>]. Following resolution of the primary infection, EBV establishes a lifelong persistence in memory B cells in which the virus remains clinically silent. In this B-cell reservoir, viral expression is entirely repressed, a process described as &#x0201c;true latency.&#x0201d; Short episodes of spontaneous reactivation and consequent viral replication normally occur in healthy individuals [<xref ref-type="bibr" rid="CR24">24</xref>]. Manifestations of liver involvement in immunocompetent hosts range from mild self-limiting acute hepatitis to occasional reports of fatal acute fulminant hepatitis. Abnormal liver blood tests are common in EBV infection and occur in up to 90 % of patients, but symptomatic hepatitis is rare [<xref ref-type="bibr" rid="CR23">23</xref>]. Jaundice is present in only 5&#x02013;10 % of cases. Typically, the rise in aminotransferases is gradual, reaching a peak that is lower than that encountered in acute viral hepatitis [<xref ref-type="bibr" rid="CR1">1</xref>]. The diagnosis is suggested by the presence of a lymphocytosis and/or splenomegaly [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>Compared with IM, which usually affects young patients, EBV hepatitis usually affects an older age group. In a recent review of nearly 2,000 cases in England, 10/17 patients (59 %) were aged &#x0003e;30, and 7/17 (41 %) were &#x02265;60 years [<xref ref-type="bibr" rid="CR23">23</xref>]. While 88 % had clinical or biochemical jaundice, 100 % had lymphocytosis, and 88 % had splenomegaly, only 12 % had the classic symptoms of IM. Symptoms lasted for a median of 8 weeks, and only 3/17 patients required a brief hospitalization. Severe cholestatic jaundice and right upper quadrant abdominal pain, which could be mistaken for bile duct obstruction, may occur in elderly patients [<xref ref-type="bibr" rid="CR25">25</xref>]. In this setting, indirect hyperbilirubinemia resulting from EBV-associated autoimmune hemolytic anemia is more commonly the cause of jaundice than viral-induced cholestasis. Other occasional clinical settings for EBV liver involvement include posttransfusion hepatitis, granulomatous hepatitis, and fatal fulminant hepatitis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. EBV superinfection may occur in patients with preexisting autoimmune hepatitis, resulting in severe hepatic decompensation [<xref ref-type="bibr" rid="CR27">27</xref>]. Cases of liver failure were described both in immunocompromised and immunocompetent hosts [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p><p>Viral replication may cause significant clinical entities and severe complications in patients with diminished cell-mediated immunity [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="Sec6"><title>EBV-Mediated Chronic Liver Damage</title><p>Chronic EBV hepatitis in immune-competent patients was suggested in several studies [<xref ref-type="bibr" rid="CR31">31</xref>]. However, EBV was not detected in human hepatocytes [<xref ref-type="bibr" rid="CR2">2</xref>]. Specific latent antigens, as well as EBER transcripts, were detected in infiltrating CD8+ CTLs, implying that hepatocytes suffer from &#x0201c;collateral&#x0201d; damage [<xref ref-type="bibr" rid="CR2">2</xref>]. Chronic hepatitis might also be induced by a soluble Fas-ligand, TNF-<italic>&#x003b1;</italic>, and IFN-&#x003b3;. Activated CD8+ cells are trapped in the liver via specific adhesive molecules expressed by Kupffer cells and sinusoidal endothelial cells [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>]. It is suggested that reactivation leading to liver damage can occur whether the infected lymphocytes are incidentally or intentionally in the liver.</p><p>Chronic active EBV infection (CAEBV) may result from a disturbance in the host&#x02013;virus balance and Th1/Th2 misbalance, and may be associated with an aggressive clinical course. CAEBV is defined by chronic severe illness, which begins as a primary EBV infection associated with elevated transaminases, abnormal EBV serology, suggestive histopathological features, and detection of viral genome in the liver tissue. Evidence of recurrent EBV reactivations, increased circulating EBV-specific CTLs, and increased CD38 B-cell expression, along with increased LDH levels, mild splenomegaly, and thrombocytopenia, can support the diagnosis [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. CAEBV may also progress to a chronic or recurrent IM-like disease [<xref ref-type="bibr" rid="CR35">35</xref>]. In Western countries, CAEBV is milder than in Asian countries [<xref ref-type="bibr" rid="CR2">2</xref>]. The mild form is characterized by intact immune control of B cells, relatively low viremia, and EBV-specific CTL expansion comparable to those of seropositive donors. Patients with iatrogenic, congenital, or acquired immunodeficiency are at increased risk for EBV-associated lymphomas and CAEBV. Immune senescence in the elderly is also associated with both reactive and neoplastic EBV-driven lymphoproliferative disorders. EBV may also trigger autoimmune hepatitis [<xref ref-type="bibr" rid="CR36">36</xref>], chronic granulomatous hepatitis [<xref ref-type="bibr" rid="CR37">37</xref>], and vanishing bile duct syndrome [<xref ref-type="bibr" rid="CR38">38</xref>]. While the existence of acute mononuclear hepatitis during primary EBV infection is accepted, skepticism has been expressed as to the hypothesis that EBV causes chronic liver disease in immune-competent patients. EBV in this setting may be referred to as an &#x0201c;incidental virus,&#x0201d; reflecting a co-infection with other hepatotropic viruses that are a more likely cause of chronic liver disease or amplification of the EBV genome in circulating B cells that turn up in the liver [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>In some patients with chronic liver disease caused by a major hepatotropic virus, a co-EBV infection was suggested. In a cohort of patients with chronic hepatitis B and C, patients with reactivated EBV infection had lower levels of HBV DNA and higher mean values of serum hepatitis C virus (HCV) RNA, respectively, compared to EBV patients without reactivation [<xref ref-type="bibr" rid="CR2">2</xref>]. EBV reactivations may precede HBV flares. Reactivation of EBV-specific T cells promotes production of several cytokines such as interferon-&#x003b3; (IFN-&#x003b3;), interleukin (IL)-1, IL-2, and IL-10. EBV BCRF1 shares high sequence homology with IL-10, and exogenous IL-10 enhances HCV replication. EBNA1 can promote HCV replication. IFN-&#x003b3; inhibits HBV replication in the absence of cell necrosis. T-cell cross-activation may also explain HBV or HCV reactivation [<xref ref-type="bibr" rid="CR2">2</xref>].</p></sec><sec id="Sec7"><title>Post-transplant Lymphoproliferative Disorder</title><p>PTLD is a spectrum of lymphoproliferative diseases occurring in the post-transplantation setting. EBV infection is the main cause of PTLD. The incidence of PTLD ranges from 0.5 to 30 % [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Risk factors for the development of PTLD include EBV-seronegativity at the time of transplantation, the type of organ transplanted, being highest in lung and heart and lowest in liver and kidney recipients, and the level and type of immune suppression (specifically anti-T-cell immunosuppression) [<xref ref-type="bibr" rid="CR39">39</xref>]. PTLD complicates up to 10 % of pediatric liver graft recipients, with a mortality of up to 50 %. In the pediatric population, post-transplant primary infection within 3 months of OLT was associated with sustained EBV detection and increased the risk of the late occurrence of PTLD [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p>PTLD emerges as either of recipient or donor origin depending on the type of transplant. Bone marrow transplant (BMT) patients develop PTLD of donor origin when EBV-infected B cells derived from the donor marrow proliferate into lymphoma. Conversely, solid organ transplant patients develop PTLD of recipient origin when EBV released from the transplanted organ infects the recipient&#x02019;s B cells [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p>The spectrum of PTLD ranges from polymorphic lymphocyte proliferation to high-grade life-threatening monoclonal lymphoma [<xref ref-type="bibr" rid="CR39">39</xref>]. The interplay between the EBV life cycle and latency and non-viral factors determines the histology and clinical presentation of the disease. The majority of PTLD is of B-cell origin. EBV&#x02019;s in vitro transforming abilities, distinctive latency, and clonality within the malignant cells determine the biology of the disease [<xref ref-type="bibr" rid="CR39">39</xref>]. Measurement of viral load by quantitative polymerase chain reaction (PCR) can assist in the surveillance and diagnosis of PTLD, although its specificity for the diagnosis is only 50 % [<xref ref-type="bibr" rid="CR39">39</xref>]. Post-transplantation patients should be monitored by EBV PCR levels in the peripheral blood with the purpose of detecting active EBV infection early and instituting preemptive therapy prior to the development of overt PTLD.</p><p>Management options for PTLD include reduction of immune suppression, biological therapy with anti-B cell antibodies, combination chemotherapy, and adoptive immunotherapy using EBV-specific CTLs [<xref ref-type="bibr" rid="CR41">41</xref>]. Surgery may be considered for localized PTLDs. Reduction of immune suppression alone results in clinical remission in 25&#x02013;63 % of adults and in 40&#x02013;86 % of pediatric PTLD patients by restoring EBV-specific immunity [<xref ref-type="bibr" rid="CR39">39</xref>]. These patients should be monitored closely for acute allograft rejection. Newer immunosuppressants, including mycophenolate mofetil and sirolimus, appear to be associated with fewer post-transplant malignancies.</p><p>Of patients with X-linked lymphoproliferative disorder (XLP), approximately 60 % may develop a severe form of IM with hemophagocytic lymphohistiocytosis and fulminant hepatitis. Treatment consists of etoposide-based chemotherapy and hematopoietic stem cell transplantation. Early treatment of primary EBV infection in these patients (prior to development of HLH) may be comprised of treatment with anti-CD20 antibodies in combination with antivirals (acyclovir or ganciclovir), IVIG, or steroids.</p></sec><sec id="Sec8"><title>EBV-Mediated Liver Cancer</title><p>EBV has been considered a major factor in the development of a wide range of cancers both in immunocompetent and immunocompromised individuals [<xref ref-type="bibr" rid="CR2">2</xref>]. EBV or infected cell clones can promote the replication of HCV and have been suggested to be involved in the development of hepatocellular carcinoma (HCC). EBV-infected cells support HCV replication better than uninfected cells, suggesting that EBV may act as a helper virus to promote HCV replication in HCV-positive HCCs. A greater amount of EBV DNA was reported in HCV-positive HCC compared to HBV-associated HCC. In some studies, up to 30 % of liver cancers were found to harbor EBV DNA [<xref ref-type="bibr" rid="CR42">42</xref>]. This finding, however, was not confirmed in other studies. A possible source of detected EBV DNA might be the infiltrating lymphocytes [<xref ref-type="bibr" rid="CR2">2</xref>]. The weak positivity of EBV DNA in some liver tissues was explained by others as possible amplification of EBV DNA in the lymphoid infiltrate or blood, reflecting a high EBV DNA load in these patients.</p></sec><sec id="Sec9"><title>Treatment of EBV Hepatitis</title><p>Primary EBV infection is subclinical in the majority of immunocompetent individuals; it may lead to IM in adolescents and adults. It is generally self-limiting; therefore, in immunocompetent individuals, symptomatic treatment alone is recommended. This includes rest, adequate hydration and nutrition, and analgesics or antipyretics as needed. In patients suffering from IM, avoidance of exertion and participation in sports is recommended for at least 3 weeks due to the rare risk of splenic rupture. Rare patients suffering from severe complications of acute EBV are usually treated with corticosteroids even though there is little evidence to support their use [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. The dose used varies in different reports. The use of antivirals in the management of severe EBV infections in immunocompetent hosts is debatable. However, it is suggested as an adjunct to steroid treatment [<xref ref-type="bibr" rid="CR45">45</xref>], especially in cases of refractory disease [<xref ref-type="bibr" rid="CR46">46</xref>]. Several antiviral drugs, including acyclic nucleoside and nucleotide analogues and pyrophosphate analogues, inhibit replication of EBV in cell culture via inhibition of EBV DNA polymerase. Acyclovir inhibits in vitro EBV replication and transiently reduces viral shedding in the oropharynx but does not reduce viremia or symptoms. Ganciclovir was effective in the treatment of EBV hepatitis in a small number of children and in adults [<xref ref-type="bibr" rid="CR47">47</xref>]. Valganciclovir, the oral pro-drug of ganciclovir, has been successfully used in the treatment of severe acute EBV hepatitis (900 mg&#x02009;&#x000d7;&#x02009;2/daily for 15 days) [<xref ref-type="bibr" rid="CR46">46</xref>]. Additional drugs with antiviral activity against EBV include valacyclovir, famciclovir, and foscarnet. Patients with acute liver failure should be considered for urgent liver transplantation, as the likelihood of spontaneous recovery is small [<xref ref-type="bibr" rid="CR48">48</xref>]. Patients with immunodeficiencies are at increased risk of liver failure and the development of lethal lymphoproliferative diseases. The major pathogenic causes thought to be important in the development of lymphoproliferative disorders/lymphomas are primary immunodeficiency (XLP, ataxia telangiectasia, Wiskott-Aldrich syndrome, Chediak-Higashi syndrome, SCID, CVID, and others), immunosuppressive therapy, and HIV/AIDS. In these patients, primary EBV infection should be treated preemptively with ex vivo-generated EBV-specific CTLs or effective antiviral medication. In seronegative patients with XLP, monthly prophylaxis with IVIG is recommended. Patients who have developed EBV-associated lymphoproliferative disease may benefit from chemotherapy, radiation therapy, or biological therapy with monoclonal antibodies or EBV-specific CTLs. Hematopoetic stem cell transplantation is the only potentially curative therapy for many patients but is usually recommended only in children [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec></sec><sec id="Sec10"><title>Cytomegalovirus</title><sec id="Sec11"><title>CMV Infection and Diagnosis</title><p>Human CMV is a double-stranded DNA virus that is the largest member of the beta herpesviridae family. The cellular response to CMV infection is characterized by cytomegaly and a spectrum of prominent clinical syndromes. The spectrum of clinical syndromes associated with CMV disease ranges from asymptomatic infection to life-threatening congenital CMV syndrome in neonates to infectious mononucleosis syndrome in young adults to severe pulmonary, retinal, neurological, gastrointestinal, and hepatic diseases in immunocompromised hosts [<xref ref-type="bibr" rid="CR1">1</xref>]. Infection can be acquired either in the perinatal period and infancy or in adulthood through sexual contact, blood transfusions, or organ transplantation [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>Serologic studies of CMV-IgM antibodies are helpful for the diagnosis of primary infections. Viral culture techniques use the &#x0201c;shell vial&#x0201d; assay and CMV early antigens. Molecular techniques to detect CMV early antigen or CMV DNA increase sensitivity for detecting CMV infection in blood and end organ tissue. To clearly establish the diagnosis of active CMV infection, it is necessary to have histological evidence of cellular injury associated with infection. Distinct pathologic findings on liver biopsy are important for the diagnosis of CMV hepatitis, especially in immunocompromised hosts. Giant multinucleated cell reaction with an inflammatory response, multifocal necrosis, and biliary stasis are common. Large nuclear inclusion-bearing cells, the so-called owl&#x02019;s eye inclusions, are detected in hepatocytes or in bile duct epithelium.</p></sec><sec id="Sec12"><title>CMV Infection in the Immunocompetent Host</title><p>The seroprevalence for CMV worldwide ranges from 60 to 100 % [<xref ref-type="bibr" rid="CR50">50</xref>]. Most primary CMV infections in immunocompetent adults are asymptomatic or associated with a mild IM syndrome. Symptomatic CMV infection in non-immunocompromised hosts has traditionally been considered to display a benign self-limited course of a disease that resembles EBV-IM syndrome. Similar to other herpes viruses, all primary infections resolve and enter into lifelong latency in which live viruses are sequestered in a non-replicative state. Persons with latent infection and intact immune systems have no symptoms but exhibit antibodies to CMV. Circulating lymphocytes, monocytes, and polymorphonuclear leukocytes may serve as the reservoir site of viral latency. The risk for intermittent reactivation is increased with immunosuppression [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>Liver dysfunction is commonly associated with CMV mononucleosis. It is usually mild and rarely symptomatic in the immunocompetent patient. Hepatosplenomegaly and laboratory evidence of mild to moderate elevation of liver enzymes are the predominant features, with increased aminotransferases and alkaline phosphatase in the majority of cases, but the levels of these are lower than are encountered in acute hepatitis due to &#x0201c;classic&#x0201d; hepatitis viruses [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Rare manifestations of CMV hepatitis include tender hepatomegaly, granulomatous hepatitis, anicteric or icteric cholestatic hepatitis, and acute hepatitis with massive necrosis [<xref ref-type="bibr" rid="CR88">88</xref>].</p><p>The morbidity and mortality that CMV infection may cause in immunocompetent hosts were recently reviewed in 290 patients [<xref ref-type="bibr" rid="CR52">52</xref>]. Severe CMV infections affected almost every system. The gastrointestinal tract (gastroenteritis, duodenitis, ileitis, colitis, proctitis) and the central nervous system (meningitis, encephalitis, transverse myelitis, nerve palsies, myeloradiculopathy) were the most frequent sites [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. In addition, hematological manifestations (hemolytic anemia and thrombocytopenia), ocular (uveitis, retinitis), liver (hepatitis), pulmonary (pneumonitis), and thrombosis of the arterial and venous system (deep venous thrombosis, portal vein thrombosis, pulmonary embolism) have been described [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Several cases were treated with ganciclovir or with valganciclovir, some with fatal outcome despite therapy.</p><p>A special population afflicted by CMV disease consists of patients with preexisting inflammatory bowel disease [<xref ref-type="bibr" rid="CR55">55</xref>]. TNF-&#x003b1; and IFN-&#x003b3; are frequently elevated in these patients and may promote reactivation of a latent CMV infection, which further promotes additional cytokine release, particularly of IL-6. This in turn leads to a vicious circle of exacerbation of the inflammatory bowel disease. This sequence of events may be observed in patients with inflammatory bowel disease who have not recently received any steroid treatment. CMV colitis in patients with underlying inflammatory bowel disease has the potential to lead to severe complications including toxic megacolon, colovesical fistula, perforation, and peritonitis.</p></sec><sec id="Sec13"><title>CMV Infection in the Immunocompromised Host</title><p>In immunocompromised patients, CMV disease results either from a primary infection or, more commonly, from reactivation of a latent infection [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Disseminated CMV infections in immunocompromised patients with impaired cell-mediated immunity, including HIV-infected patients, transplant recipients, and congenitally infected patients, are associated with increased morbidity and mortality. Anti-CMV antibodies are detected during episodes of reactivation. However, the incidence and severity of CMV disease closely parallels the degree of cellular immune dysfunction, characterized by decreased numbers of CTLs and natural killer cells [<xref ref-type="bibr" rid="CR56">56</xref>]. The clinical syndromes observed in these patients include encephalitis, pneumonitis, hepatitis, uveitis, retinitis, colitis, and graft rejection. CMV infection affecting the human embryo, a host with immature immunologic responses, may lead to serious complications such as microcephaly, mental retardation, spastic paralysis, hepatosplenomegaly, anemia, thrombocytopenia, deafness, and optic nerve atrophy leading to blindness [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p>CMV is the most common opportunistic viral infection in AIDS patients, causing retinitis, central nervous system infections, esophagitis, and colitis. CMV may also invade the hepatobiliary tract in AIDS patients, causing hepatitis, pancreatitis, and acute acalculous cholecystitis [<xref ref-type="bibr" rid="CR57">57</xref>]. The presence of CMV retinitis, gastrointestinal disease, or viremia in AIDS patients increases the risk for a cholestatic syndrome caused by papillary stenosis and sclerosing cholangitis (AIDS cholangiopathy), which does not usually respond to antiviral therapy. Hepatitis is the most frequent organ-specific complication of CMV infection after liver transplantation, affecting 10 % of recipients and with a higher incidence among seronegative recipients than seropositive patients (26 % vs. 9 %, respectively). In these cases, infection occurs as a consequence of reactivation rather than primary infection [<xref ref-type="bibr" rid="CR1">1</xref>].</p></sec><sec id="Sec14"><title>Treatment of CMV Infection</title><p>The current opinion is that CMV infection in immunocompetent patients does not require treatment [<xref ref-type="bibr" rid="CR52">52</xref>]. Data on a need for antiviral treatment in immunocompetent patients with severe CMV infection is conflicting. The improvement observed in some treated patients may have been related to the typically self-limiting course of the disease and thus cannot be attributed with certainty to a treatment effect [<xref ref-type="bibr" rid="CR45">45</xref>].</p><p>For severe cases, particularly in patients with impaired cell-mediated immunity, therapy can be life-saving [<xref ref-type="bibr" rid="CR1">1</xref>]. Drugs approved for treatment of CMV disease include ganciclovir, valganciclovir, foscarnet, and cidofovir. Ganciclovir is considered the antiviral agent of choice against CMV. The duration of therapy is guided by repeated measurements of CMV in blood samples. Emerging strains resistant to ganciclovir pose a therapeutic challenge for which foscarnet or cidofovir may become alternative antiviral agents [<xref ref-type="bibr" rid="CR58">58</xref>]. Valganciclovir has recently been evaluated among liver transplant recipients with CMV disease [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Ganciclovir can lead to myelosuppression, central nervous system disorders, hepatotoxicity, irreversible infertility, or teratogenesis, whereas foscarnet can cause disturbances in mineral and electrolyte homeostasis and nephrotoxicity. Long-term administration of these agents may lead to the emergence of resistant viral strains [<xref ref-type="bibr" rid="CR45">45</xref>].</p></sec><sec id="Sec15"><title>CMV in Liver Transplant Recipients</title><p>CMV infection is a common complication following liver transplantation and contributes to morbidity and mortality in these patients [<xref ref-type="bibr" rid="CR56">56</xref>]. CMV evades the immune system resulting in a state of latency in several types of host cells. Cellular sites of viral latency become reservoirs of reactivation during periods of stress and cytokine release and serve as vehicles for transmission to susceptible hosts. Pharmacologically induced impairment of immune response to &#x0201c;endogenously reactivated&#x0201d; or &#x0201c;allograft-transmitted&#x0201d; CMV leads to febrile and tissue-invasive diseases in liver transplant recipients [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p>Overall, 18&#x02013;29 % of liver transplant recipients will develop CMV disease [<xref ref-type="bibr" rid="CR59">59</xref>]. A lack of preexisting CMV-specific immunity in CMV-seronegative recipients of liver allograft from CMV-seropositive donors (CMV D+/R&#x02212;) exposes these patients to the highest risk of CMV disease and its complications (44&#x02013;65 % in CMV D+/R&#x02212; vs. 8&#x02013;19 % in CMV-seropositive recipients, CMV R+) [<xref ref-type="bibr" rid="CR60">60</xref>]. The incidence is reduced in liver transplant recipients who receive antiviral prophylaxis with valganciclovir or oral ganciclovir for the first 3 months following liver transplantation. CMV disease rates of 12&#x02013;30 % in high-risk CMV D+/R&#x02212; and less than 10 % in CMV R+ were reported in patients who received antiviral prophylaxis [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. A recent randomized control trial showed that 200 days of prophylaxis are more effective than 100 days of therapy in high-risk (D+/R&#x02212;) patients; however, this has yet to become a standard recommendation due to safety and cost [<xref ref-type="bibr" rid="CR62">62</xref>]. In individuals who received antiviral prophylaxis, CMV disease may occur 3&#x02013;6 months after completing antiviral prophylaxis; hence, the term &#x0201c;delayed-onset&#x0201d; or &#x0201c;late-onset&#x0201d; CMV disease [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p>The use of highly potent pharmacologic immune suppression severely impairs the ability of liver transplant recipients to mount an effective immune response against reactivating CMV, thereby predisposing them to increased risk of CMV disease [<xref ref-type="bibr" rid="CR60">60</xref>]. The severity of immune dysfunction is strongest with lymphocyte-depleting drugs such as anti-CD3 and antithymocyte globulin [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p>Defects in innate and in CMV-specific cell-mediated immunity predispose these patients to severe infections. Mutations in innate immunity-associated genes increase the risk of CMV disease after liver transplantation. TLR2 expressed in innate immune cells senses the glycoprotein B of CMV, thereby signaling immune cells to produce cytokines and antiviral peptides. In a study of 92 liver transplant recipients, a genetic polymorphism in the TLR-2 gene was associated with a higher degree of CMV replication and a higher incidence of CMV disease. This polymorphism decreased the cellular recognition of CMV by TLR2-expressing cells. Programmed death-1 receptor expression and immune evasion genes have also been assessed as prognostic indicators of CMV disease following liver transplantation.</p><p>CMV disease in liver recipients manifests with fever, bone marrow suppression, and organ-invasive disease. These direct clinical effects are classified as CMV syndrome (fever with myelosuppression) or as tissue-invasive CMV disease, which most often involves the gastrointestinal tract (CMV gastritis, esophagitis, enteritis, and colitis), although any organ may be involved. CMV hepatitis is common in liver transplant recipients compared to other solid organ transplant recipients and manifests with symptoms indistinguishable from acute allograft rejection [<xref ref-type="bibr" rid="CR56">56</xref>]. The availability of sensitive tests for the rapid detection of CMV in the blood may obviate the need for a liver biopsy to differentiate CMV infection from rejection. However, in many cases, a liver biopsy is required to differentiate or demonstrate a coexistence of CMV disease and allograft rejection.</p><p>Several indirect outcomes in these patients are mediated by the ability of the virus to modulate the immune system [<xref ref-type="bibr" rid="CR56">56</xref>]. CMV is known to be a potent up-regulator of alloantigens, thereby increasing the risk of acute rejection and chronic allograft dysfunction. CMV is associated with vanishing bile duct syndrome and ductopenic rejection, leading to chronic cholestasis and allograft failure and with a higher incidence of hepatic artery thrombosis. The immunomodulatory effects of CMV predispose to other opportunistic infections including fungi, other viruses, and bacteria such as <italic>Nocardia</italic>. CMV-infected transplant recipients are more likely to develop EBV-associated PTLD or to develop coinfections with other viruses such as human herpes virus HHV6 and HHV7 [<xref ref-type="bibr" rid="CR63">63</xref>]. An association between CMV and an accelerated course of HCV recurrence was described [<xref ref-type="bibr" rid="CR64">64</xref>]. Forty-eight percent of HCV-transplanted patients who developed CMV disease had allograft loss or died within 3 years of transplantation, compared to 35 % of patients with asymptomatic CMV infection and 17 % of those who did not develop CMV infection [<xref ref-type="bibr" rid="CR64">64</xref>].</p><p>CMV infection is an independent predictor of mortality after solid organ transplantation. The use of anti-CMV drugs, either through antiviral prophylaxis or preemptive therapy, led to reduction in the overall mortality after solid organ transplantation. An analysis of 437 liver transplant recipients demonstrated that CMV disease occurred in 8.5 % of the patients and that its occurrence was independently associated with a fivefold increased risk of all-cause mortality and an 11-fold increased risk of infection-related mortality [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p>Allograft rejection can promote CMV reactivation and is a significant risk factor for CMV disease following liver transplantation [<xref ref-type="bibr" rid="CR56">56</xref>]. Cytokines released during acute rejection, particularly TNF-&#x003b1;, are potent activators of latent CMV. Therapy for allograft rejection, which involves intensification of the immunosuppressive regimen, further increases the risk of CMV disease. The risk of CMV disease after liver transplantation is associated in direct proportion with the degree of CMV replication, which is partly a function of &#x0201c;over-immunosuppression&#x0201d; [<xref ref-type="bibr" rid="CR66">66</xref>].</p><p>There are two strategies for CMV disease prevention after liver transplantation: preemptive therapy and antiviral prophylaxis [<xref ref-type="bibr" rid="CR56">56</xref>]. For preemptive therapy, CMV reactivation is monitored by sensitive assays; upon detection, antiviral drugs are administered early to halt progression of the asymptomatic infection to full-blown clinical disease [<xref ref-type="bibr" rid="CR67">67</xref>]. Preemptive therapy with oral ganciclovir or intravenous ganciclovir or valganciclovir resulted in reduction of CMV disease by 70 % [<xref ref-type="bibr" rid="CR68">68</xref>], and, unlike antiviral prophylaxis, was not associated with late-onset CMV disease. Valganciclovir is currently the most commonly used drug for preemptive therapy. Preemptive therapy may not be completely effective in CMV D+/R&#x02212; liver transplant recipients because the replication kinetics of CMV in immune deficient individuals is very rapid [<xref ref-type="bibr" rid="CR66">66</xref>].</p><p>For antiviral prophylaxis, antiviral drugs such as ganciclovir and valganciclovir are administered to patients at risk of CMV disease after liver transplantation [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR69">69</xref>&#x02013;<xref ref-type="bibr" rid="CR73">73</xref>]. While there is no clear consensus regarding antiviral prophylaxis, it is administered by the majority of transplant centers for prevention of primary CMV disease in high-risk CMV D+/R&#x02212; transplant recipients [<xref ref-type="bibr" rid="CR74">74</xref>]. Prophylaxis is recommended in all CMV D+/R&#x02212; liver recipients [<xref ref-type="bibr" rid="CR75">75</xref>]. Several clinical trials have demonstrated its effectiveness in preventing the direct and indirect effects of CMV after liver transplantation [<xref ref-type="bibr" rid="CR68">68</xref>]. Compared to placebo, patients who received antiviral prophylaxis had a 58&#x02013;80 % reduction in CMV disease and a 40 % reduction in CMV infection [<xref ref-type="bibr" rid="CR68">68</xref>]. The use of acyclovir as anti-CMV prophylaxis after liver transplantation has been supplanted by ganciclovir and valganciclovir because of their superior efficacy [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Prophylactic versus preemptive therapy for intermediate- and low-risk groups (D+/R+, D&#x02212;/R+, and D&#x02212;/R&#x02212;, respectively) is based on the local expertise of each transplant center. However, the general approach for D&#x02212;/R&#x02212; patients is that only seronegative blood products are used and no prophylaxis is administered. D+/R+ or D&#x02212;/R+ patients are monitored for CMV reactivation and treated preemptively for 7 days. Where available, &#x0201c;protective matching&#x0201d; of donor and recipient based on CMV serological status is advocated because it has been shown to reduce the risk of post-transplant CMV disease [<xref ref-type="bibr" rid="CR69">69</xref>]. The current recommendation for antiviral treatment of CMV disease after liver transplantation is intravenous ganciclovir along with a reduction in the degree of pharmacologic immunosuppression [<xref ref-type="bibr" rid="CR78">78</xref>]. Valganciclovir is a possible oral treatment for mild to moderate disease [<xref ref-type="bibr" rid="CR78">78</xref>]. In cases of ganciclovir-resistant CMV disease, treatment options include foscarnet, cidofovir, CMV hyperimmune globulins, or leflunomide [<xref ref-type="bibr" rid="CR69">69</xref>]. Compartmentalized CMV disease refers to clinical syndromes wherein the virus is detected in the affected tissues but is minimally detectable or undetectable in the blood [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. In the gastrointestinal system, &#x0201c;compartmentalized&#x0201d; CMV disease in the form of gastritis, esophagitis, enteritis, or colitis constitutes the vast majority of tissue-invasive conditions [<xref ref-type="bibr" rid="CR60">60</xref>].</p></sec></sec><sec id="Sec16"><title>Herpes Simplex Virus</title><p>Herpes simplex viruses, HSV-1 and HSV-2, commonly infect humans and produce a wide variety of illnesses. The clinical manifestations and course of HSV infections depend on the site involved and patient&#x02019;s age and immune status [<xref ref-type="bibr" rid="CR1">1</xref>]. HSV viremia results in visceral involvement, affecting mainly the esophagus, lungs, and liver. Liver involvement occurs in neonatal infections, pregnancy, and immunocompromised hosts, where it is frequently a fulminant disease [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>HSV is an uncommon cause of hepatitis in immunocompetent patients. A mild asymptomatic elevation of aminotransferase levels can be detected in 14 % of healthy adults with genital infection [<xref ref-type="bibr" rid="CR79">79</xref>]. Fulminant hepatitis with more than 100-fold rise in aminotransferases was reported and associated with a favorable outcome after antiviral therapy [<xref ref-type="bibr" rid="CR80">80</xref>]. The incidence of HSV hepatitis was reported to be up to 6 % of fulminant hepatitis cases.</p><p>In immunocompromised hosts, HSV hepatitis has occurred during primary and, rarely, during recurrent infection, with a triad of fever, leukopenia and markedly elevated liver enzymes, as well as thrombocytopenia and a relatively mild increase in bilirubin [<xref ref-type="bibr" rid="CR1">1</xref>]. Liver biopsy is essential to establish the diagnosis of HSV hepatitis. It shows focal, sometimes extensive, hemorrhagic, or coagulative, necrosis of the hepatocytes with limited inflammatory response. Typical intranuclear inclusions (Cowdry type A) are often identified at the margins of the foci of necrosis. The diagnosis is confirmed by detection of HSV DNA sequences by molecular techniques [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>In neonates, hepatitis occurs with multi-organ involvement and carries a high mortality rate. In pregnant women, it is observed in the context of disseminated primary infection during the third trimester and presenting as fulminant hepatitis. Mucocutaneous lesions are present in only half of cases; thus, many cases are not diagnosed until autopsy. Early diagnosis and treatment with antiviral therapy may reverse an otherwise fatal process [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>The treatment of choice in these patients is early high-dose acyclovir [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Recurrence was not observed, suggesting that disseminated HSV infection should not be an absolute contraindication for transplantation in certain clinical settings [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>].</p><p>The importance of additional human herpes viruses (HHV6 and 7) has been debated in recent years. According to some series, HHV6-infected patients have higher rates of acute and chronic allograft rejection, bacterial and opportunistic infections, a higher risk for CMV disease, and shorter graft survival [<xref ref-type="bibr" rid="CR85">85</xref>]. While HHV6 reactivation is common after solid organ transplantation, clinical disease is rare, manifesting as fever, myelosuppression, and end organ disease including encephalitis and hepatitis. Treatment is indicated for end organ disease and includes foscarnet, ganciclovir, and cidofovir [<xref ref-type="bibr" rid="CR86">86</xref>].</p></sec><sec id="Sec17"><title>Varicella Zoster Virus</title><p>Primary varicella infection is usually benign with mild transient elevation in liver enzymes in up to 25 % of children; however, it can cause severe acute hepatitis and even ALF in immune-competent adults. In transplanted patients, primary infection can present with an aggressive liver disease [<xref ref-type="bibr" rid="CR1">1</xref>]. Such infection may occur in the immediate postoperative period or up to several months after liver transplantation and is usually associated with rapid onset and fatal hepatitis [<xref ref-type="bibr" rid="CR87">87</xref>]. Serologic testing is of little value in immunocompromised patients. Confirmation of diagnosis is made through isolation of VZV from skin lesions or from the affected organs. Liver biopsy often shows foci of coagulative necrosis and intranuclear inclusions with an inflammatory response [<xref ref-type="bibr" rid="CR1">1</xref>]. Early administration of intravenous acyclovir is critical in the setting of VZV hepatitis, especially in immunocompromised patients [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR88">88</xref>].</p></sec><sec id="Sec18"><title>Parvovirus (B19)</title><p>Parvovirus (B19), a small DNA virus, is a member of the parvoviridae family. Its clinical manifestations include erythema infectiosum, hydrops fetalis and fetal death in children, and arthritis in adults. Leucopenia, thrombocytopenia, and aplastic crisis in patients with chronic hemolytic anemia are additional features. Rare manifestations include neurological, cardiac, and hepatic end organ damage and vasculitis. Hepatic manifestations range from mild transient hepatitis to acute liver failure with or without associated aplastic anemia. Infection is usually benign and self-limiting, and symptomatic therapy alone is recommended [<xref ref-type="bibr" rid="CR1">1</xref>].</p></sec><sec id="Sec19"><title>Adenoviruses</title><p>There are 50 different serotypes of adenoviruses that cause acute infections of the respiratory system, conjunctivae, and gastrointestinal tract and occasionally hemorrhagic cystitis, infantile diarrhea, intussusception, and central nervous system infections [<xref ref-type="bibr" rid="CR1">1</xref>]. Multi-organ involvement has been reported in immunocompromised, and rarely in immunocompetent, patients, associated with increased mortality [<xref ref-type="bibr" rid="CR89">89</xref>]. Fatal cases of adenovirus infection with fulminant hepatitis were reported in immunosuppressed adults [<xref ref-type="bibr" rid="CR90">90</xref>]. No specific therapy for adenovirus hepatitis is currently available, and cidofovir has been recently suggested as an optional treatment [<xref ref-type="bibr" rid="CR1">1</xref>].</p></sec><sec id="Sec20"><title>Additional Viruses That May Cause Hepatitis</title><p>Several viruses may involve the liver as a part of an acute viral infection (Table <xref rid="Tab1" ref-type="table">12.1</xref>). This infection may manifest as mild hepatitis and rarely as severe hepatitis and liver failure, along with other severe manifestations such as hemorrhagic fever. Therapy is supportive with anecdotal reports supporting antiviral therapy. Patients with liver failure should be considered for urgent liver transplantation; however, this may be hindered by concomitant damage to other organs.</p></sec></body><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallegos-Orozco</surname><given-names>JF</given-names></name><name><surname>Rakela-Brodner</surname><given-names>J</given-names></name></person-group><article-title>Hepatitis viruses: not always what it seems to be</article-title><source>Rev Med Chil</source><year>2010</year><volume>138</volume><fpage>1302</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.4067/S0034-98872010001100016</pub-id><?supplied-pmid 21279280?><pub-id pub-id-type="pmid">21279280</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>M</given-names></name><name><surname>Kamburov</surname><given-names>V</given-names></name></person-group><article-title>Epstein-Barr virus: silent companion or causative agent of chronic liver disease?</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>4130</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i33.4130</pub-id><?supplied-pmid 20806428?><pub-id pub-id-type="pmid">20806428</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savard</surname><given-names>M</given-names></name><name><surname>Gosselin</surname><given-names>J</given-names></name></person-group><article-title>Epstein-Barr virus immunosuppression of innate immunity mediated by phagocytes</article-title><source>Virus Res</source><year>2006</year><volume>119</volume><fpage>134</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2006.02.008</pub-id><?supplied-pmid 16545476?><pub-id pub-id-type="pmid">16545476</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martorelli</surname><given-names>D</given-names></name><name><surname>Muraro</surname><given-names>E</given-names></name><name><surname>Merlo</surname><given-names>A</given-names></name><name><surname>Turrini</surname><given-names>R</given-names></name><name><surname>Fae</surname><given-names>DA</given-names></name><name><surname>Rosato</surname><given-names>A</given-names></name><name><surname>Dolcetti</surname><given-names>R</given-names></name></person-group><article-title>Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders</article-title><source>Clin Dev Immunol</source><year>2012</year><volume>2012</volume><fpage>931952</fpage><pub-id pub-id-type="doi">10.1155/2012/931952</pub-id><?supplied-pmid 22319542?><pub-id pub-id-type="pmid">22319542</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ressing</surname><given-names>ME</given-names></name><name><surname>Horst</surname><given-names>D</given-names></name><name><surname>Griffin</surname><given-names>BD</given-names></name><name><surname>Tellam</surname><given-names>J</given-names></name><name><surname>Zuo</surname><given-names>J</given-names></name><name><surname>Khanna</surname><given-names>R</given-names></name><name><surname>Rowe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products</article-title><source>Semin Cancer Biol</source><year>2008</year><volume>18</volume><fpage>397</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2008.10.008</pub-id><?supplied-pmid 18977445?><pub-id pub-id-type="pmid">18977445</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>LS</given-names></name><name><surname>Rickinson</surname><given-names>AB</given-names></name></person-group><article-title>Epstein-Barr virus: 40 years on</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>757</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/nrc1452</pub-id><?supplied-pmid 15510157?><pub-id pub-id-type="pmid">15510157</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markin</surname><given-names>RS</given-names></name></person-group><article-title>Manifestations of Epstein-Barr virus-associated disorders in liver</article-title><source>Liver</source><year>1994</year><volume>14</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0676.1994.tb00001.x</pub-id><?supplied-pmid 8177024?><pub-id pub-id-type="pmid">8177024</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>N</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Morishima</surname><given-names>T</given-names></name></person-group><article-title>Virological aspects of Epstein-Barr virus infections</article-title><source>Acta Med Okayama</source><year>2005</year><volume>59</volume><fpage>239</fpage><lpage>46</lpage><?supplied-pmid 16418766?><pub-id pub-id-type="pmid">16418766</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strowig</surname><given-names>T</given-names></name><name><surname>Brilot</surname><given-names>F</given-names></name><name><surname>Munz</surname><given-names>C</given-names></name></person-group><article-title>Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity</article-title><source>J Immunol</source><year>2008</year><volume>180</volume><fpage>7785</fpage><lpage>91</lpage><?supplied-pmid 18523242?><pub-id pub-id-type="pmid">18523242</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strowig</surname><given-names>T</given-names></name><name><surname>Brilot</surname><given-names>F</given-names></name><name><surname>Arrey</surname><given-names>F</given-names></name><name><surname>Bougras</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Muller</surname><given-names>WA</given-names></name><name><surname>Munz</surname><given-names>C</given-names></name></person-group><article-title>Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma</article-title><source>PLoS Pathog</source><year>2008</year><volume>4</volume><fpage>e27</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.0040027</pub-id><?supplied-pmid 18266470?><pub-id pub-id-type="pmid">18266470</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>S</given-names></name></person-group><article-title>Innate immune modulation in EBV infection</article-title><source>Herpesviridae</source><year>2011</year><volume>2</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/2042-4280-2-1</pub-id><?supplied-pmid 21429244?><pub-id pub-id-type="pmid">21429244</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levitsky</surname><given-names>V</given-names></name><name><surname>Masucci</surname><given-names>MG</given-names></name></person-group><article-title>Manipulation of immune responses by Epstein-Barr virus</article-title><source>Virus Res</source><year>2002</year><volume>88</volume><fpage>71</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/S0168-1702(02)00121-1</pub-id><?supplied-pmid 12297328?><pub-id pub-id-type="pmid">12297328</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagoya</surname><given-names>Y</given-names></name><name><surname>Hangaishi</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Kurokawa</surname><given-names>M</given-names></name></person-group><article-title>High-dose dexamethasone therapy for severe thrombocytopenia and neutropenia induced by EBV infectious mononucleosis</article-title><source>Int J Hematol</source><year>2010</year><volume>91</volume><fpage>326</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s12185-009-0485-0</pub-id><?supplied-pmid 20082159?><pub-id pub-id-type="pmid">20082159</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larochelle</surname><given-names>B</given-names></name><name><surname>Flamand</surname><given-names>L</given-names></name><name><surname>Gourde</surname><given-names>P</given-names></name><name><surname>Beauchamp</surname><given-names>D</given-names></name><name><surname>Gosselin</surname><given-names>J</given-names></name></person-group><article-title>Epstein-Barr virus infects and induces apoptosis in human neutrophils</article-title><source>Blood</source><year>1998</year><volume>92</volume><fpage>291</fpage><lpage>9</lpage><?supplied-pmid 9639529?><pub-id pub-id-type="pmid">9639529</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YL</given-names></name><name><surname>Li</surname><given-names>M</given-names></name></person-group><article-title>Human cytomegalovirus and Epstein-Barr virus inhibit oral bacteria-induced macrophage activation and phagocytosis</article-title><source>Oral Microbiol Immunol</source><year>2009</year><volume>24</volume><fpage>243</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1399-302X.2009.00504.x</pub-id><?supplied-pmid 19416455?><pub-id pub-id-type="pmid">19416455</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mautner</surname><given-names>J</given-names></name><name><surname>Bornkamm</surname><given-names>GW</given-names></name></person-group><article-title>The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection</article-title><source>Eur J Cell Biol</source><year>2012</year><volume>91</volume><fpage>31</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.ejcb.2011.01.007</pub-id><?supplied-pmid 21458882?><pub-id pub-id-type="pmid">21458882</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>KM</given-names></name><name><surname>Young</surname><given-names>LS</given-names></name></person-group><article-title>Epstein-Barr virus and carcinogenesis: beyond Burkitt&#x02019;s lymphoma</article-title><source>Clin Microbiol Infect</source><year>2009</year><volume>15</volume><fpage>982</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2009.03033.x</pub-id><?supplied-pmid 19874382?><pub-id pub-id-type="pmid">19874382</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>M</given-names></name><name><surname>Muhtarova</surname><given-names>M</given-names></name><name><surname>Nikolova</surname><given-names>M</given-names></name><name><surname>Magaev</surname><given-names>S</given-names></name><name><surname>Taskov</surname><given-names>H</given-names></name><name><surname>Nikolovska</surname><given-names>D</given-names></name><name><surname>Krastev</surname><given-names>Z</given-names></name></person-group><article-title>Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients</article-title><source>World J Gastroenterol</source><year>2006</year><volume>12</volume><fpage>5711</fpage><lpage>6</lpage><?supplied-pmid 17007027?><pub-id pub-id-type="pmid">17007027</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Baarle</surname><given-names>D</given-names></name><name><surname>Tsegaye</surname><given-names>A</given-names></name><name><surname>Miedema</surname><given-names>F</given-names></name><name><surname>Akbar</surname><given-names>A</given-names></name></person-group><article-title>Significance of senescence for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system</article-title><source>Immunol Lett</source><year>2005</year><volume>97</volume><fpage>19</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2004.10.003</pub-id><?supplied-pmid 15626472?><pub-id pub-id-type="pmid">15626472</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wills</surname><given-names>MR</given-names></name><name><surname>Okecha</surname><given-names>G</given-names></name><name><surname>Weekes</surname><given-names>MP</given-names></name><name><surname>Gandhi</surname><given-names>MK</given-names></name><name><surname>Sissons</surname><given-names>PJ</given-names></name><name><surname>Carmichael</surname><given-names>AJ</given-names></name></person-group><article-title>Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8(+) T cell response</article-title><source>J Immunol</source><year>2002</year><volume>168</volume><fpage>5455</fpage><lpage>64</lpage><?supplied-pmid 12023339?><pub-id pub-id-type="pmid">12023339</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hislop</surname><given-names>AD</given-names></name><name><surname>Taylor</surname><given-names>GS</given-names></name><name><surname>Sauce</surname><given-names>D</given-names></name><name><surname>Rickinson</surname><given-names>AB</given-names></name></person-group><article-title>Cellular responses to viral infection in humans: lessons from Epstein-Barr virus</article-title><source>Annu Rev Immunol</source><year>2007</year><volume>25</volume><fpage>587</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.25.022106.141553</pub-id><?supplied-pmid 17378764?><pub-id pub-id-type="pmid">17378764</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JI</given-names></name></person-group><article-title>Epstein-Barr virus infection</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>481</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1056/NEJM200008173430707</pub-id><?supplied-pmid 10944566?><pub-id pub-id-type="pmid">10944566</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vine</surname><given-names>LJ</given-names></name><name><surname>Shepherd</surname><given-names>K</given-names></name><name><surname>Hunter</surname><given-names>JG</given-names></name><name><surname>Madden</surname><given-names>R</given-names></name><name><surname>Thornton</surname><given-names>C</given-names></name><name><surname>Ellis</surname><given-names>V</given-names></name><name><surname>Bendall</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Characteristics of Epstein-Barr virus hepatitis among patients with jaundice or acute hepatitis</article-title><source>Aliment Pharmacol Ther</source><year>2012</year><volume>36</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2012.05122.x</pub-id><?supplied-pmid 22554291?><pub-id pub-id-type="pmid">22554291</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name></person-group><article-title>T cells and viral persistence: lessons from diverse infections</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><fpage>873</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ni1241</pub-id><?supplied-pmid 16116467?><pub-id pub-id-type="pmid">16116467</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaukat</surname><given-names>A</given-names></name><name><surname>Tsai</surname><given-names>HT</given-names></name><name><surname>Rutherford</surname><given-names>R</given-names></name><name><surname>Anania</surname><given-names>FA</given-names></name></person-group><article-title>Epstein-Barr virus induced hepatitis: an important cause of cholestasis</article-title><source>Hepatol Res</source><year>2005</year><volume>33</volume><fpage>24</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.hepres.2005.06.005</pub-id><?supplied-pmid 16112900?><pub-id pub-id-type="pmid">16112900</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okano</surname><given-names>M</given-names></name><name><surname>Gross</surname><given-names>TG</given-names></name></person-group><article-title>Acute or chronic life-threatening diseases associated with Epstein-Barr virus infection</article-title><source>Am J Med Sci</source><year>2012</year><volume>343</volume><fpage>483</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/MAJ.0b013e318236e02d</pub-id><?supplied-pmid 22104426?><pub-id pub-id-type="pmid">22104426</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koay</surname><given-names>LB</given-names></name><name><surname>Tsai</surname><given-names>SL</given-names></name><name><surname>Sun</surname><given-names>CS</given-names></name><name><surname>Wu</surname><given-names>KT</given-names></name></person-group><article-title>Chronic autoimmune hepatitis with Epstein-Barr virus superinfection: a case report and review of literature</article-title><source>Hepatogastroenterology</source><year>2008</year><volume>55</volume><fpage>1781</fpage><lpage>4</lpage><?supplied-pmid 19102393?><pub-id pub-id-type="pmid">19102393</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ader</surname><given-names>F</given-names></name><name><surname>Chatellier</surname><given-names>D</given-names></name><name><surname>Le Berre</surname><given-names>R</given-names></name><name><surname>Morand</surname><given-names>P</given-names></name><name><surname>Fourrier</surname><given-names>F</given-names></name></person-group><article-title>Fulminant Epstein-Barr virus (EBV) hepatitis in a young immunocompetent subject</article-title><source>Med Mal Infect</source><year>2006</year><volume>36</volume><fpage>396</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.medmal.2006.03.002</pub-id><?supplied-pmid 16876362?><pub-id pub-id-type="pmid">16876362</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname><given-names>T</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Yokosuka</surname><given-names>O</given-names></name><name><surname>Imazeki</surname><given-names>F</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Fukai</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Fatal chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis</article-title><source>Eur J Gastroenterol Hepatol</source><year>2004</year><volume>16</volume><fpage>225</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/00042737-200402000-00017</pub-id><?supplied-pmid 15075999?><pub-id pub-id-type="pmid">15075999</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babel</surname><given-names>N</given-names></name><name><surname>Schwarzmann</surname><given-names>F</given-names></name><name><surname>Prang</surname><given-names>N</given-names></name><name><surname>Jaeger</surname><given-names>M</given-names></name><name><surname>Wolf</surname><given-names>H</given-names></name><name><surname>Kern</surname><given-names>F</given-names></name><name><surname>Volk</surname><given-names>HD</given-names></name><etal/></person-group><article-title>Association between Epstein-Barr virus infection and late acute transplant rejection in long-term transplant patients</article-title><source>Transplantation</source><year>2001</year><volume>72</volume><fpage>736</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/00007890-200108270-00031</pub-id><?supplied-pmid 11544441?><pub-id pub-id-type="pmid">11544441</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drebber</surname><given-names>U</given-names></name><name><surname>Kasper</surname><given-names>HU</given-names></name><name><surname>Krupacz</surname><given-names>J</given-names></name><name><surname>Haferkamp</surname><given-names>K</given-names></name><name><surname>Kern</surname><given-names>MA</given-names></name><name><surname>Steffen</surname><given-names>HM</given-names></name><name><surname>Quasdorff</surname><given-names>M</given-names></name><etal/></person-group><article-title>The role of Epstein-Barr virus in acute and chronic hepatitis</article-title><source>J Hepatol</source><year>2006</year><volume>44</volume><fpage>879</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2006.02.006</pub-id><?supplied-pmid 16554102?><pub-id pub-id-type="pmid">16554102</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehal</surname><given-names>WZ</given-names></name></person-group><article-title>Intrahepatic T, cell survival versus death: which one prevails and why?</article-title><source>J Hepatol</source><year>2003</year><volume>39</volume><fpage>1070</fpage><lpage>1</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2003.10.005</pub-id><?supplied-pmid 14642628?><pub-id pub-id-type="pmid">14642628</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehal</surname><given-names>WZ</given-names></name><name><surname>Azzaroli</surname><given-names>F</given-names></name><name><surname>Crispe</surname><given-names>IN</given-names></name></person-group><article-title>Immunology of the healthy liver: old questions and new insights</article-title><source>Gastroenterology</source><year>2001</year><volume>120</volume><fpage>250</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1053/gast.2001.20947</pub-id><?supplied-pmid 11208734?><pub-id pub-id-type="pmid">11208734</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crispe</surname><given-names>IN</given-names></name><name><surname>Dao</surname><given-names>T</given-names></name><name><surname>Klugewitz</surname><given-names>K</given-names></name><name><surname>Mehal</surname><given-names>WZ</given-names></name><name><surname>Metz</surname><given-names>DP</given-names></name></person-group><article-title>The liver as a site of T-cell apoptosis: graveyard, or killing field?</article-title><source>Immunol Rev</source><year>2000</year><volume>174</volume><fpage>47</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0528.2002.017412.x</pub-id><?supplied-pmid 10807506?><pub-id pub-id-type="pmid">10807506</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straus</surname><given-names>SE</given-names></name></person-group><article-title>The chronic mononucleosis syndrome</article-title><source>J Infect Dis</source><year>1988</year><volume>157</volume><fpage>405</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1093/infdis/157.3.405</pub-id><?supplied-pmid 2830340?><pub-id pub-id-type="pmid">2830340</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vento</surname><given-names>S</given-names></name><name><surname>Cainelli</surname><given-names>F</given-names></name></person-group><article-title>Is there a role for viruses in triggering autoimmune hepatitis?</article-title><source>Autoimmun Rev</source><year>2004</year><volume>3</volume><fpage>61</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S1568-9972(03)00053-3</pub-id><?supplied-pmid 14871651?><pub-id pub-id-type="pmid">14871651</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biest</surname><given-names>S</given-names></name><name><surname>Schubert</surname><given-names>TT</given-names></name></person-group><article-title>Chronic Epstein-Barr virus infection: a cause of granulomatous hepatitis?</article-title><source>J Clin Gastroenterol</source><year>1989</year><volume>11</volume><fpage>343</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/00004836-198906000-00021</pub-id><?supplied-pmid 2546990?><pub-id pub-id-type="pmid">2546990</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>K</given-names></name><name><surname>Miyakawa</surname><given-names>H</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Fujikawa</surname><given-names>H</given-names></name><name><surname>Horiuchi</surname><given-names>T</given-names></name><name><surname>Nagai</surname><given-names>K</given-names></name><name><surname>Kako</surname><given-names>M</given-names></name></person-group><article-title>Vanishing bile duct syndrome associated with chronic EBV infection</article-title><source>Dig Dis Sci</source><year>2000</year><volume>45</volume><fpage>160</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1023/A:1005434015863</pub-id><?supplied-pmid 10695629?><pub-id pub-id-type="pmid">10695629</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamdar</surname><given-names>KY</given-names></name><name><surname>Rooney</surname><given-names>CM</given-names></name><name><surname>Heslop</surname><given-names>HE</given-names></name></person-group><article-title>Posttransplant lymphoproliferative disease following liver transplantation</article-title><source>Curr Opin Organ Transplant</source><year>2011</year><volume>16</volume><fpage>274</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1097/MOT.0b013e3283465715</pub-id><?supplied-pmid 21467936?><pub-id pub-id-type="pmid">21467936</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Antiga</surname><given-names>L</given-names></name><name><surname>Del Rizzo</surname><given-names>M</given-names></name><name><surname>Mengoli</surname><given-names>C</given-names></name><name><surname>Cillo</surname><given-names>U</given-names></name><name><surname>Guariso</surname><given-names>G</given-names></name><name><surname>Zancan</surname><given-names>L</given-names></name></person-group><article-title>Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD</article-title><source>Liver Transpl</source><year>2007</year><volume>13</volume><fpage>343</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/lt.20958</pub-id><?supplied-pmid 17154402?><pub-id pub-id-type="pmid">17154402</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>Sugawara</surname><given-names>Y</given-names></name><name><surname>Ota</surname><given-names>S</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Fukayama</surname><given-names>M</given-names></name><etal/></person-group><article-title>Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature</article-title><source>Leuk Lymphoma</source><year>2010</year><volume>51</volume><fpage>1494</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.3109/10428194.2010.492063</pub-id><?supplied-pmid 20578817?><pub-id pub-id-type="pmid">20578817</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>BA</given-names></name><name><surname>Zeng</surname><given-names>YM</given-names></name><name><surname>Chen</surname><given-names>GC</given-names></name><name><surname>Li</surname><given-names>XX</given-names></name><name><surname>Chen</surname><given-names>JT</given-names></name><name><surname>Guo</surname><given-names>YW</given-names></name><etal/></person-group><article-title>Epstein-Barr virus in hepatocellular carcinogenesis</article-title><source>World J Gastroenterol</source><year>2004</year><volume>10</volume><fpage>3409</fpage><lpage>13</lpage><?supplied-pmid 15526357?><pub-id pub-id-type="pmid">15526357</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luzuriaga</surname><given-names>K</given-names></name><name><surname>Sullivan</surname><given-names>JL</given-names></name></person-group><article-title>Infectious mononucleosis</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>1993</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.1056/NEJMcp1001116</pub-id><?supplied-pmid 20505178?><pub-id pub-id-type="pmid">20505178</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Candy B, Hotopf M. Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst Rev. 2006;CD004402.</mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rafailidis</surname><given-names>PI</given-names></name><name><surname>Mavros</surname><given-names>MN</given-names></name><name><surname>Kapaskelis</surname><given-names>A</given-names></name><name><surname>Falagas</surname><given-names>ME</given-names></name></person-group><article-title>Antiviral treatment for severe EBV infections in apparently immunocompetent patients</article-title><source>J Clin Virol</source><year>2010</year><volume>49</volume><fpage>151</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2010.07.008</pub-id><?supplied-pmid 20739216?><pub-id pub-id-type="pmid">20739216</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisapia</surname><given-names>R</given-names></name><name><surname>Mariano</surname><given-names>A</given-names></name><name><surname>Rianda</surname><given-names>A</given-names></name><name><surname>Testa</surname><given-names>A</given-names></name><name><surname>Oliva</surname><given-names>A</given-names></name><name><surname>Vincenzi</surname><given-names>L</given-names></name></person-group><article-title>Severe EBV hepatitis treated with valganciclovir</article-title><source>Infection</source><year>2013</year><volume>41</volume><fpage>251</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1007/s15010-012-0303-0</pub-id><?supplied-pmid 22837057?><pub-id pub-id-type="pmid">22837057</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>LA</given-names></name><name><surname>Deboer</surname><given-names>B</given-names></name><name><surname>Jeffrey</surname><given-names>G</given-names></name><name><surname>Marley</surname><given-names>R</given-names></name><name><surname>Garas</surname><given-names>G</given-names></name></person-group><article-title>Ganciclovir and the treatment of Epstein-Barr virus hepatitis</article-title><source>J Gastroenterol Hepatol</source><year>2006</year><volume>21</volume><fpage>1758</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2006.03257.x</pub-id><?supplied-pmid 16984606?><pub-id pub-id-type="pmid">16984606</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feranchak</surname><given-names>AP</given-names></name><name><surname>Tyson</surname><given-names>RW</given-names></name><name><surname>Narkewicz</surname><given-names>MR</given-names></name><name><surname>Karrer</surname><given-names>FM</given-names></name><name><surname>Sokol</surname><given-names>RJ</given-names></name></person-group><article-title>Fulminant Epstein-Barr viral hepatitis: orthotopic liver transplantation and review of the literature</article-title><source>Liver Transpl Surg</source><year>1998</year><volume>4</volume><fpage>469</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1002/lt.500040612</pub-id><?supplied-pmid 9791157?><pub-id pub-id-type="pmid">9791157</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okano</surname><given-names>M</given-names></name><name><surname>Gross</surname><given-names>TG</given-names></name></person-group><article-title>Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients</article-title><source>Expert Rev Anti Infect Ther</source><year>2007</year><volume>5</volume><fpage>403</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1586/14787210.5.3.403</pub-id><?supplied-pmid 17547505?><pub-id pub-id-type="pmid">17547505</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staras</surname><given-names>SA</given-names></name><name><surname>Dollard</surname><given-names>SC</given-names></name><name><surname>Radford</surname><given-names>KW</given-names></name><name><surname>Flanders</surname><given-names>WD</given-names></name><name><surname>Pass</surname><given-names>RF</given-names></name><name><surname>Cannon</surname><given-names>MJ</given-names></name></person-group><article-title>Seroprevalence of cytomegalovirus infection in the United States, 1988&#x02013;1994</article-title><source>Clin Infect Dis</source><year>2006</year><volume>43</volume><fpage>1143</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1086/508173</pub-id><?supplied-pmid 17029132?><pub-id pub-id-type="pmid">17029132</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunno</surname><given-names>A</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Murakami</surname><given-names>K</given-names></name></person-group><article-title>Clinical and histological features of cytomegalovirus hepatitis in previously healthy adults</article-title><source>Liver</source><year>1997</year><volume>17</volume><fpage>129</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0676.1997.tb00794.x</pub-id><?supplied-pmid 9249726?><pub-id pub-id-type="pmid">9249726</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rafailidis</surname><given-names>PI</given-names></name><name><surname>Mourtzoukou</surname><given-names>EG</given-names></name><name><surname>Varbobitis</surname><given-names>IC</given-names></name><name><surname>Falagas</surname><given-names>ME</given-names></name></person-group><article-title>Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review</article-title><source>Virol J</source><year>2008</year><volume>5</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-5-47</pub-id><?supplied-pmid 18371229?><pub-id pub-id-type="pmid">18371229</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galiatsatos</surname><given-names>P</given-names></name><name><surname>Shrier</surname><given-names>I</given-names></name><name><surname>Lamoureux</surname><given-names>E</given-names></name><name><surname>Szilagyi</surname><given-names>A</given-names></name></person-group><article-title>Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts</article-title><source>Dig Dis Sci</source><year>2005</year><volume>50</volume><fpage>609</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s10620-005-2544-6</pub-id><?supplied-pmid 15844689?><pub-id pub-id-type="pmid">15844689</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karakozis</surname><given-names>S</given-names></name><name><surname>Gongora</surname><given-names>E</given-names></name><name><surname>Caceres</surname><given-names>M</given-names></name><name><surname>Brun</surname><given-names>E</given-names></name><name><surname>Cook</surname><given-names>JW</given-names></name></person-group><article-title>Life-threatening cytomegalovirus colitis in the immunocompetent patient: report of a case and review of the literature</article-title><source>Dis Colon Rectum</source><year>2001</year><volume>44</volume><fpage>1716</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/BF02234398</pub-id><?supplied-pmid 11711750?><pub-id pub-id-type="pmid">11711750</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Zafiri</surname><given-names>R</given-names></name><name><surname>Gologan</surname><given-names>A</given-names></name><name><surname>Galiatsatos</surname><given-names>P</given-names></name><name><surname>Szilagyi</surname><given-names>A</given-names></name></person-group><article-title>Cytomegalovirus complicating inflammatory bowel disease: a 10-year experience in a community-based, university-affiliated hospital</article-title><source>Gastroenterol Hepatol (N Y)</source><year>2012</year><volume>8</volume><fpage>230</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22723754</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razonable</surname><given-names>RR</given-names></name></person-group><article-title>Cytomegalovirus infection after liver transplantation: current concepts and challenges</article-title><source>World J Gastroenterol</source><year>2008</year><volume>14</volume><fpage>4849</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.3748/wjg.14.4849</pub-id><?supplied-pmid 18756591?><pub-id pub-id-type="pmid">18756591</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roulot</surname><given-names>D</given-names></name><name><surname>Valla</surname><given-names>D</given-names></name><name><surname>Brun-Vezinet</surname><given-names>F</given-names></name><name><surname>Rey</surname><given-names>MA</given-names></name><name><surname>Clavel</surname><given-names>F</given-names></name><name><surname>Degott</surname><given-names>C</given-names></name><name><surname>Guillan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cholangitis in the acquired immunodeficiency syndrome: report of two cases and review of the literature</article-title><source>Gut</source><year>1987</year><volume>28</volume><fpage>1653</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1136/gut.28.12.1653</pub-id><?supplied-pmid 3322961?><pub-id pub-id-type="pmid">3322961</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr</suffix></name></person-group><article-title>Antiviral drugs</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>1255</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1056/NEJM199904223401608</pub-id><?supplied-pmid 10210711?><pub-id pub-id-type="pmid">10210711</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name></person-group><article-title>Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients</article-title><source>Clin Infect Dis</source><year>2008</year><volume>47</volume><fpage>296</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1086/589577</pub-id><?supplied-pmid 18564941?><pub-id pub-id-type="pmid">18564941</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arthurs</surname><given-names>SK</given-names></name><name><surname>Eid</surname><given-names>AJ</given-names></name><name><surname>Pedersen</surname><given-names>RA</given-names></name><name><surname>Dierkhising</surname><given-names>RA</given-names></name><name><surname>Kremers</surname><given-names>WK</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Razonable</surname><given-names>RR</given-names></name></person-group><article-title>Delayed-onset primary cytomegalovirus disease after liver transplantation</article-title><source>Liver Transpl</source><year>2007</year><volume>13</volume><fpage>1703</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/lt.21280</pub-id><?supplied-pmid 18044717?><pub-id pub-id-type="pmid">18044717</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>HY</given-names></name><name><surname>Wagener</surname><given-names>MM</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name></person-group><article-title>Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review</article-title><source>Am J Transplant</source><year>2008</year><volume>8</volume><fpage>2111</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2008.02369.x</pub-id><?supplied-pmid 18828771?><pub-id pub-id-type="pmid">18828771</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arthurs</surname><given-names>SK</given-names></name><name><surname>Eid</surname><given-names>AJ</given-names></name><name><surname>Deziel</surname><given-names>PJ</given-names></name><name><surname>Marshall</surname><given-names>WF</given-names></name><name><surname>Cassivi</surname><given-names>SD</given-names></name><name><surname>Walker</surname><given-names>RC</given-names></name><name><surname>Razonable</surname><given-names>RR</given-names></name></person-group><article-title>The impact of invasive fungal diseases on survival after lung transplantation</article-title><source>Clin Transplant</source><year>2010</year><volume>24</volume><fpage>341</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0012.2009.01076.x</pub-id><?supplied-pmid 19712081?><pub-id pub-id-type="pmid">19712081</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>JC</given-names></name><name><surname>Dockrell</surname><given-names>DH</given-names></name><name><surname>Espy</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>TF</given-names></name><name><surname>Wilson</surname><given-names>JA</given-names></name><name><surname>Harmsen</surname><given-names>WS</given-names></name><name><surname>Ilstrup</surname><given-names>D</given-names></name><etal/></person-group><article-title>Human beta-herpesvirus interactions in solid organ transplant recipients</article-title><source>J Infect Dis</source><year>2001</year><volume>183</volume><fpage>179</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1086/317929</pub-id><?supplied-pmid 11120923?><pub-id pub-id-type="pmid">11120923</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burak</surname><given-names>KW</given-names></name><name><surname>Kremers</surname><given-names>WK</given-names></name><name><surname>Batts</surname><given-names>KP</given-names></name><name><surname>Wiesner</surname><given-names>RH</given-names></name><name><surname>Rosen</surname><given-names>CB</given-names></name><name><surname>Razonable</surname><given-names>RR</given-names></name><name><surname>Paya</surname><given-names>CV</given-names></name><etal/></person-group><article-title>Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C</article-title><source>Liver Transpl</source><year>2002</year><volume>8</volume><fpage>362</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1053/jlts.2002.32282</pub-id><?supplied-pmid 11965581?><pub-id pub-id-type="pmid">11965581</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limaye</surname><given-names>AP</given-names></name><name><surname>Bakthavatsalam</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>HW</given-names></name><name><surname>Randolph</surname><given-names>SE</given-names></name><name><surname>Halldorson</surname><given-names>JB</given-names></name><name><surname>Healey</surname><given-names>PJ</given-names></name><name><surname>Kuhr</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis</article-title><source>Transplantation</source><year>2006</year><volume>81</volume><fpage>1645</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1097/01.tp.0000226071.12562.1a</pub-id><?supplied-pmid 16794529?><pub-id pub-id-type="pmid">16794529</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emery</surname><given-names>VC</given-names></name><name><surname>Sabin</surname><given-names>CA</given-names></name><name><surname>Cope</surname><given-names>AV</given-names></name><name><surname>Gor</surname><given-names>D</given-names></name><name><surname>Hassan-Walker</surname><given-names>AF</given-names></name><name><surname>Griffiths</surname><given-names>PD</given-names></name></person-group><article-title>Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>2032</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02350-3</pub-id><?supplied-pmid 10885354?><pub-id pub-id-type="pmid">10885354</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>JK</given-names></name><name><surname>Scholz</surname><given-names>LM</given-names></name><name><surname>Scheetz</surname><given-names>MH</given-names></name><name><surname>Gallon</surname><given-names>LG</given-names></name><name><surname>Kaufman</surname><given-names>DB</given-names></name><name><surname>Rachwalski</surname><given-names>EJ</given-names></name><name><surname>Abecassis</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction</article-title><source>Transplantation</source><year>2007</year><volume>83</volume><fpage>874</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1097/01.tp.0000257923.69422.4d</pub-id><?supplied-pmid 17460557?><pub-id pub-id-type="pmid">17460557</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodson</surname><given-names>EM</given-names></name><name><surname>Jones</surname><given-names>CA</given-names></name><name><surname>Webster</surname><given-names>AC</given-names></name><name><surname>Strippoli</surname><given-names>GF</given-names></name><name><surname>Barclay</surname><given-names>PG</given-names></name><name><surname>Kable</surname><given-names>K</given-names></name><name><surname>Vimalachandra</surname><given-names>D</given-names></name><etal/></person-group><article-title>Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>2105</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)66553-1</pub-id><?supplied-pmid 15964447?><pub-id pub-id-type="pmid">15964447</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eid</surname><given-names>AJ</given-names></name><name><surname>Razonable</surname><given-names>RR</given-names></name></person-group><article-title>New developments in the management of cytomegalovirus infection after solid organ transplantation</article-title><source>Drugs</source><year>2010</year><volume>70</volume><fpage>965</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.2165/10898540-000000000-00000</pub-id><?supplied-pmid 20481654?><pub-id pub-id-type="pmid">20481654</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badley</surname><given-names>AD</given-names></name><name><surname>Seaberg</surname><given-names>EC</given-names></name><name><surname>Porayko</surname><given-names>MK</given-names></name><name><surname>Wiesner</surname><given-names>RH</given-names></name><name><surname>Keating</surname><given-names>MR</given-names></name><name><surname>Wilhelm</surname><given-names>MP</given-names></name><name><surname>Walker</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database</article-title><source>Transplantation</source><year>1997</year><volume>64</volume><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1097/00007890-199707150-00013</pub-id><?supplied-pmid 9233703?><pub-id pub-id-type="pmid">9233703</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gane</surname><given-names>E</given-names></name><name><surname>Saliba</surname><given-names>F</given-names></name><name><surname>Valdecasas</surname><given-names>GJ</given-names></name><name><surname>O&#x02019;Grady</surname><given-names>J</given-names></name><name><surname>Pescovitz</surname><given-names>MD</given-names></name><name><surname>Lyman</surname><given-names>S</given-names></name><name><surname>Robinson</surname><given-names>CA</given-names></name></person-group><article-title>Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]</article-title><source>Lancet</source><year>1997</year><volume>350</volume><fpage>1729</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(97)05535-9</pub-id><?supplied-pmid 9413463?><pub-id pub-id-type="pmid">9413463</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lautenschlager</surname><given-names>I</given-names></name></person-group><article-title>CMV infection, diagnosis and antiviral strategies after liver transplantation</article-title><source>Transpl Int</source><year>2009</year><volume>22</volume><fpage>1031</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/j.1432-2277.2009.00907.x</pub-id><?supplied-pmid 19619175?><pub-id pub-id-type="pmid">19619175</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watt</surname><given-names>K</given-names></name><name><surname>Veldt</surname><given-names>B</given-names></name><name><surname>Charlton</surname><given-names>M</given-names></name></person-group><article-title>A practical guide to the management of HCV infection following liver transplantation</article-title><source>Am J Transplant</source><year>2009</year><volume>9</volume><fpage>1707</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2009.02702.x</pub-id><?supplied-pmid 19538491?><pub-id pub-id-type="pmid">19538491</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Wannstedt</surname><given-names>C</given-names></name><name><surname>Keyes</surname><given-names>L</given-names></name><name><surname>Wagener</surname><given-names>MM</given-names></name><name><surname>Gayowski</surname><given-names>T</given-names></name><name><surname>Cacciarelli</surname><given-names>TV</given-names></name></person-group><article-title>Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years</article-title><source>Transplantation</source><year>2005</year><volume>79</volume><fpage>1428</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1097/01.TP.0000157867.98649.F5</pub-id><?supplied-pmid 15912115?><pub-id pub-id-type="pmid">15912115</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opelz</surname><given-names>G</given-names></name><name><surname>Dohler</surname><given-names>B</given-names></name><name><surname>Ruhenstroth</surname><given-names>A</given-names></name></person-group><article-title>Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report</article-title><source>Am J Transplant</source><year>2004</year><volume>4</volume><fpage>928</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2004.00451.x</pub-id><?supplied-pmid 15147427?><pub-id pub-id-type="pmid">15147427</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limaye</surname><given-names>AP</given-names></name></person-group><article-title>Ganciclovir-resistant cytomegalovirus in organ transplant recipients</article-title><source>Clin Infect Dis</source><year>2002</year><volume>35</volume><fpage>866</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1086/342385</pub-id><?supplied-pmid 12228824?><pub-id pub-id-type="pmid">12228824</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paya</surname><given-names>C</given-names></name><name><surname>Humar</surname><given-names>A</given-names></name><name><surname>Dominguez</surname><given-names>E</given-names></name><name><surname>Washburn</surname><given-names>K</given-names></name><name><surname>Blumberg</surname><given-names>E</given-names></name><name><surname>Alexander</surname><given-names>B</given-names></name><name><surname>Freeman</surname><given-names>R</given-names></name><etal/></person-group><article-title>Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients</article-title><source>Am J Transplant</source><year>2004</year><volume>4</volume><fpage>611</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2004.00382.x</pub-id><?supplied-pmid 15023154?><pub-id pub-id-type="pmid">15023154</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asberg</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>CN</given-names></name><name><surname>Reubsaet</surname><given-names>L</given-names></name></person-group><article-title>Determination of ganciclovir in different matrices from solid organ transplanted patients treated with a wide range of concomitant drugs</article-title><source>J Pharm Biomed Anal</source><year>2007</year><volume>43</volume><fpage>1039</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2006.08.022</pub-id><?supplied-pmid 17034976?><pub-id pub-id-type="pmid">17034976</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minuk</surname><given-names>GY</given-names></name><name><surname>Nicolle</surname><given-names>LE</given-names></name></person-group><article-title>Genital herpes and hepatitis in healthy young adults</article-title><source>J Med Virol</source><year>1986</year><volume>19</volume><fpage>269</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1002/jmv.1890190309</pub-id><?supplied-pmid 3016168?><pub-id pub-id-type="pmid">3016168</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>DJ</given-names></name><name><surname>Greene</surname><given-names>WH</given-names></name><name><surname>Ruggiero</surname><given-names>F</given-names></name><name><surname>McGarrity</surname><given-names>TJ</given-names></name></person-group><article-title>Herpes simplex-induced fulminant hepatitis in adults: a call for empiric therapy</article-title><source>Dig Dis Sci</source><year>2000</year><volume>45</volume><fpage>2399</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1023/A:1005699210816</pub-id><?supplied-pmid 11258565?><pub-id pub-id-type="pmid">11258565</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glorioso</surname><given-names>DV</given-names></name><name><surname>Molloy</surname><given-names>PJ</given-names></name><name><surname>Van Thiel</surname><given-names>DH</given-names></name><name><surname>Kania</surname><given-names>RJ</given-names></name></person-group><article-title>Successful empiric treatment of HSV hepatitis in pregnancy. Case report and review of the literature</article-title><source>Dig Dis Sci</source><year>1996</year><volume>41</volume><fpage>1273</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/BF02088248</pub-id><?supplied-pmid 8654163?><pub-id pub-id-type="pmid">8654163</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>B</given-names></name><name><surname>Gandhi</surname><given-names>SA</given-names></name><name><surname>Louie</surname><given-names>E</given-names></name><name><surname>Rizzi</surname><given-names>R</given-names></name><name><surname>Illei</surname><given-names>P</given-names></name></person-group><article-title>Herpes simplex virus hepatitis: case report and review</article-title><source>Clin Infect Dis</source><year>1997</year><volume>24</volume><fpage>334</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/clinids/24.3.334</pub-id><?supplied-pmid 9114181?><pub-id pub-id-type="pmid">9114181</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinna</surname><given-names>AD</given-names></name><name><surname>Rakela</surname><given-names>J</given-names></name><name><surname>Demetris</surname><given-names>AJ</given-names></name><name><surname>Fung</surname><given-names>JJ</given-names></name></person-group><article-title>Five cases of fulminant hepatitis due to herpes simplex virus in adults</article-title><source>Dig Dis Sci</source><year>2002</year><volume>47</volume><fpage>750</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1023/A:1014779614525</pub-id><?supplied-pmid 11991604?><pub-id pub-id-type="pmid">11991604</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norvell</surname><given-names>JP</given-names></name><name><surname>Blei</surname><given-names>AT</given-names></name><name><surname>Jovanovic</surname><given-names>BD</given-names></name><name><surname>Levitsky</surname><given-names>J</given-names></name></person-group><article-title>Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases</article-title><source>Liver Transpl</source><year>2007</year><volume>13</volume><fpage>1428</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1002/lt.21250</pub-id><?supplied-pmid 17902129?><pub-id pub-id-type="pmid">17902129</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampaio</surname><given-names>AM</given-names></name><name><surname>Guardia</surname><given-names>AC</given-names></name><name><surname>Milan</surname><given-names>A</given-names></name><name><surname>Sasaki</surname><given-names>AN</given-names></name><name><surname>Andrade</surname><given-names>PD</given-names></name><name><surname>Bonon</surname><given-names>SH</given-names></name><name><surname>Stucchi</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Co-infection and clinical impact of human Herpesvirus 5 and 6 in liver transplantation</article-title><source>Transplant Proc</source><year>2012</year><volume>44</volume><fpage>2455</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2012.07.034</pub-id><?supplied-pmid 23026619?><pub-id pub-id-type="pmid">23026619</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lautenschlager</surname><given-names>I</given-names></name><name><surname>Razonable</surname><given-names>RR</given-names></name></person-group><article-title>Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review</article-title><source>Transpl Int</source><year>2012</year><volume>25</volume><fpage>493</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1111/j.1432-2277.2012.01443.x</pub-id><?supplied-pmid 22356254?><pub-id pub-id-type="pmid">22356254</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patti</surname><given-names>ME</given-names></name><name><surname>Selvaggi</surname><given-names>KJ</given-names></name><name><surname>Kroboth</surname><given-names>FJ</given-names></name></person-group><article-title>Varicella hepatitis in the immunocompromised adult: a case report and review of the literature</article-title><source>Am J Med</source><year>1990</year><volume>88</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(90)90133-X</pub-id><?supplied-pmid 2403757?><pub-id pub-id-type="pmid">2403757</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alford</surname><given-names>CA</given-names></name></person-group><article-title>Acyclovir treatment of herpes simplex virus infections in immunocompromised humans. An overview</article-title><source>Am J Med</source><year>1982</year><volume>73</volume><fpage>225</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(82)90096-1</pub-id><?supplied-pmid 6285714?><pub-id pub-id-type="pmid">6285714</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>M</given-names></name><name><surname>Cheung</surname><given-names>R</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name></person-group><article-title>Adenovirus-induced acute liver failure</article-title><source>Dig Dis Sci</source><year>2009</year><volume>54</volume><fpage>218</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/s10620-008-0628-9</pub-id><?supplied-pmid 19034647?><pub-id pub-id-type="pmid">19034647</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmichael</surname><given-names>GP</given-names><suffix>Jr</suffix></name><name><surname>Zahradnik</surname><given-names>JM</given-names></name><name><surname>Moyer</surname><given-names>GH</given-names></name><name><surname>Porter</surname><given-names>DD</given-names></name></person-group><article-title>Adenovirus hepatitis in an immunosuppressed adult patient</article-title><source>Am J Clin Pathol</source><year>1979</year><volume>71</volume><fpage>352</fpage><lpage>5</lpage><?supplied-pmid 219683?><pub-id pub-id-type="pmid">219683</pub-id></element-citation></ref></ref-list></back></article>